<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="018f6cc1-75d3-4bda-9e36-03f1858e70a5"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use EPYSQLI safely and effectively. See full prescribing information for EPYSQLI.<br/>
      <br/>EPYSQLI<sup>Â®</sup> (eculizumab-aagh) injection, for intravenous use<br/>Initial U.S. Approval: 2024<br/>
      <content styleCode="Nobold">EPYSQLI (eculizumab-aagh) is biosimilar<footnote>Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of EPYSQLI has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information.</footnote> to SOLIRIS (eculizumab).</content>
   </title>
   <effectiveTime value="20250402"/>
   <setId root="1fa1aa80-1c59-44d4-9841-b6c52882651b"/>
   <versionNumber value="2"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="001627975" root="1.3.6.1.4.1.519.1"/>
            <name>Teva Pharmaceuticals USA, Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="dcl-dpl">
               <id root="c3079ee4-22ee-4163-920b-8f7c4ba42e41"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20250402"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="51759-208" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>EPYSQLI</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Eculizumab-aagh</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="300" unit="mg"/>
                              <denominator value="30" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="A3ULP0F556" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Eculizumab</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="A3ULP0F556" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Eculizumab</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>polysorbate 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70WT22SF4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>sodium phosphate, dibasic, heptahydrate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="593YOG76RN" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>sodium phosphate, monobasic, monohydrate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7YIN7J07X4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>trehalose dihydrate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Water</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="mL"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="51759-208-13" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250407"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250407"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="BLA761340" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="s1">
               <id root="b935ee7a-9fc3-4a50-8876-e71fe3f6973a"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>WARNING: SERIOUS MENINGOCOCCAL INFECTIONS</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Eculizumab products, complement inhibitors, increase the risk of serious infections caused by</content>
                     <content styleCode="bold italics">Neisseria meningitidis</content>
                     <content styleCode="bold">[</content>
                     <content styleCode="bold italics">see Warnings and Precautions (<linkHtml href="#s18">5.1</linkHtml>)</content>
                     <content styleCode="bold">]. Life-threatening and fatal meningococcal infections have occurred in patients treated with complement inhibitors. These infections may become rapidly life-threatening or fatal if not recognized and treated early.</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>
                        <content styleCode="bold">Complete or update vaccination for meningococcal bacteria (for serogroups A, C, W, Y, and B) at least 2 weeks prior to the first dose of EPYSQLI, unless the risks of delaying therapy with EPYSQLI outweigh the risk of developing a serious infection. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for vaccinations against meningococcal bacteria in patients receiving a complement inhibitor. See</content>
                        <content styleCode="bold italics">Warnings and Precautions</content>
                        <content styleCode="bold">(<linkHtml href="#s18">5.1</linkHtml>) for additional guidance on the management of the risk of serious infections caused by meningococcal bacteria.</content>
                     </item>
                     <item>
                        <content styleCode="bold">Patients receiving eculizumab products are at increased risk for invasive disease caused by</content>
                        <content styleCode="bold italics">Neisseria meningitidis</content>
                        <content styleCode="bold">, even if they develop antibodies following vaccination. Monitor patients for early signs and symptoms of serious meningococcal infections and evaluate immediately if infection is suspected.</content>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Because of the risk of serious meningococcal infections, EPYSQLI is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called EPYSQLI REMS [</content>
                     <content styleCode="bold italics">see Warnings and Precautions (<linkHtml href="#s19">5.2</linkHtml>)</content>
                     <content styleCode="bold">].</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250402"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">WARNING: SERIOUS MENINGOCOCCAL INFECTIONS</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold italics">See full prescribing information for complete boxed warning.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Eculizumab products increase the risk of serious and life-threatening infections caused by</content>
                           <content styleCode="bold italics">Neisseria meningitidis.</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="bold">Complete or update meningococcal vaccination at least 2 weeks prior to the first dose of EPYSQLI, unless the risks of delaying EPYSQLI outweigh the risk of developing a serious infection. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for meningococcal vaccination in patients receiving a complement inhibitor. (<linkHtml href="#s18">5.1</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="bold">Patients receiving eculizumab products are at increased risk for invasive disease caused by</content>
                              <content styleCode="bold italics">N. meningitidis</content>
                              <content styleCode="bold">, even if they develop antibodies following vaccination. Monitor patients for early signs and symptoms of meningococcal infections, and evaluate immediately if infection is suspected. (<linkHtml href="#s18">5.1</linkHtml>)</content>
                           </item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">EPYSQLI is available only through a restricted program called the EPYSQLI REMS. (<linkHtml href="#s19">5.2</linkHtml>)</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section>
               <id root="83ca3c74-90d9-42e7-be03-3c746f4c26c3"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20250402"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%" styleCode="Noautorules">
                           <col width="90%" align="left" valign="top"/>
                           <col width="10%" align="right" valign="top"/>
                           <tbody>
                              <tr>
                                 <td>Indications and Usage (<linkHtml href="#s6">1.3</linkHtml>)</td>
                                 <td>01/2025</td>
                              </tr>
                              <tr>
                                 <td>Dosage and Administration (<linkHtml href="#s11">2.4</linkHtml>, <linkHtml href="#s12">2.5</linkHtml>)</td>
                                 <td>01/2025</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s2">
               <id root="a2065d17-7450-4ffd-8cd7-102d4625a0bf"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1  INDICATIONS AND USAGE</title>
               <effectiveTime value="20250402"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>EPYSQLI is a complement inhibitor indicated for:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. (<linkHtml href="#s3">1.1</linkHtml>)</item>
                           <item>the treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy. (<linkHtml href="#s4">1.2</linkHtml>)<br/>
                              <content styleCode="underline">Limitation of Use<br/>
                              </content>EPYSQLI is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS).</item>
                           <item>the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) antibody positive. (<linkHtml href="#s6">1.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s3">
                     <id root="49b6d1c3-c591-4967-b70f-4c75de96898e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1 Paroxysmal Nocturnal Hemoglobinuria (PNH)</title>
                     <text>
                        <paragraph>EPYSQLI is indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis.</paragraph>
                     </text>
                     <effectiveTime value="20250402"/>
                  </section>
               </component>
               <component>
                  <section ID="s4">
                     <id root="b7ab24cf-75f4-4ed2-8955-4bd8ab9aa87f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2 Atypical Hemolytic Uremic Syndrome (aHUS)</title>
                     <text>
                        <paragraph>EPYSQLI is indicated for the treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy.</paragraph>
                     </text>
                     <effectiveTime value="20250402"/>
                     <component>
                        <section ID="s5">
                           <id root="d0ef93bf-f116-43fb-841e-9d91d28459e9"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Limitation of Use</content>
                              </paragraph>
                              <paragraph>EPYSQLI is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS).</paragraph>
                           </text>
                           <effectiveTime value="20250402"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s6">
                     <id root="04819068-28d5-4cd3-856e-b4b3b48c7fc9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.3 Generalized Myasthenia Gravis (gMG)</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">EPYSQLI is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) antibody positive.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250402"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s7">
               <id root="6c4f0247-3d03-4315-9437-1c34a74fbfe0"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2  DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250402"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>For intravenous infusion only</paragraph>
                        <paragraph>PNH Dosage Regimen: (<linkHtml href="#s9">2.2</linkHtml>)</paragraph>
                        <paragraph>aHUS Dosage Regimen: (<linkHtml href="#s10">2.3</linkHtml>)</paragraph>
                        <paragraph>gMG Dosage Regimen: (<linkHtml href="#s11">2.4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s8">
                     <id root="835ce359-d928-40bf-a1c8-1dc487832f8c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1  Recommended Vaccination and Prophylaxis for Meningococcal Infection</title>
                     <text>
                        <paragraph>Vaccinate patients against meningococcal infection (serogroups A, C, W, Y, and B) according to current ACIP recommendations at least 2 weeks prior to initiation of EPYSQLI [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#s18">5.1</linkHtml>)</content>].</paragraph>
                        <paragraph>If urgent EPYSQLI therapy is indicated in a patient who is not up to date with meningococcal vaccines according to ACIP recommendations, provide the patient with antibacterial drug prophylaxis and administer these vaccines as soon as possible.</paragraph>
                        <paragraph>Healthcare providers who prescribe EPYSQLI must enroll in the EPYSQLI REMS <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s19">5.2</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250402"/>
                  </section>
               </component>
               <component>
                  <section ID="s9">
                     <id root="6e3da61c-854d-4e4b-bfed-8738e624816c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2  Recommended Dosage Regimen â PNH</title>
                     <text>
                        <paragraph>For patients 18 years of age and older, EPYSQLI therapy consists of:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>600 mg weekly for the first 4 weeks, followed by</item>
                           <item>900 mg for the fifth dose 1 week later, then</item>
                           <item>900 mg every 2 weeks thereafter.</item>
                        </list>
                        <paragraph>Administer EPYSQLI at the recommended dosage regimen time points, or within two days of these time points [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#s21">5.4</linkHtml>)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20250402"/>
                  </section>
               </component>
               <component>
                  <section ID="s10">
                     <id root="621768a7-8a5b-47c4-b71a-8134f45bdba8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Recommended Dosage Regimen â aHUS</title>
                     <text>
                        <paragraph>For patients 18 years of age and older, EPYSQLI therapy consists of:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>900 mg weekly for the first 4 weeks, followed by</item>
                           <item>1,200 mg for the fifth dose 1 week later, then</item>
                           <item>1,200 mg every 2 weeks thereafter.</item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">For patients less than 18 years of age, administer EPYSQLI based upon body weight, according to the following schedule (<linkHtml href="#t1">Table 1</linkHtml>):</content>
                        </paragraph>
                        <table ID="t1" width="100%">
                           <caption>Table 1: Dosing Recommendations in aHUS Patients Less Than 18 Years of Age</caption>
                           <col width="30.367%" align="left"/>
                           <col width="27.633%" align="left"/>
                           <col width="42.000%" align="left"/>
                           <tbody>
                              <tr>
                                 <td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule">
                                    <content styleCode="bold">Patient Body Weight</content>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">Induction</content>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">Maintenance</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="middle" styleCode="Botrule Lrule Rrule">40 kg and over</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">900 mg weekly x 4 doses</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">1,200 mg at week 5;<br/>then 1,200 mg every 2 weeks</td>
                              </tr>
                              <tr>
                                 <td align="center" valign="middle" styleCode="Botrule Lrule Rrule">30 kg to less than 40 kg</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">600 mg weekly x 2 doses</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">900 mg at week 3;<br/>then 900 mg every 2 weeks</td>
                              </tr>
                              <tr>
                                 <td align="center" valign="middle" styleCode="Botrule Lrule Rrule">20 kg to less than 30 kg</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">600 mg weekly x 2 doses</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">600 mg at week 3;<br/>then 600 mg every 2 weeks</td>
                              </tr>
                              <tr>
                                 <td align="center" valign="middle" styleCode="Botrule Lrule Rrule">10 kg to less than 20 kg</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">600 mg weekly x 1 dose</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">300 mg at week 2;<br/>then 300 mg every 2 weeks</td>
                              </tr>
                              <tr>
                                 <td align="center" valign="middle" styleCode="Botrule Lrule Rrule">5 kg to less than 10 kg</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">300 mg weekly x 1 dose</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">300 mg at week 2;<br/>then 300 mg every 3 weeks</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Administer EPYSQLI at the recommended dosage regimen time points, or within two days of these time points.</paragraph>
                     </text>
                     <effectiveTime value="20250402"/>
                  </section>
               </component>
               <component>
                  <section ID="s11">
                     <id root="960dc964-9619-47c6-9ca7-23a8bf26c3ab"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Recommended Dosage Regimen â gMG</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">For adult patients with generalized myasthenia gravis, EPYSQLI therapy consists of:</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="xmChange">900 mg weekly for the first 4 weeks, followed by</content>
                           </item>
                           <item>
                              <content styleCode="xmChange">1,200 mg for the fifth dose 1 week later, then</content>
                           </item>
                           <item>
                              <content styleCode="xmChange">1,200 mg every 2 weeks thereafter.</content>
                           </item>
                        </list>
                        <paragraph>
                           <content styleCode="xmChange">Administer EPYSQLI at the recommended dosage regimen time points, or within two days of these time points.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250402"/>
                  </section>
               </component>
               <component>
                  <section ID="s12">
                     <id root="24093919-aa28-49dd-a23d-1e3455bfb193"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5 Dose Adjustment in Case of Plasmapheresis, Plasma Exchange, or Fresh Frozen Plasma Infusion</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">For adult and pediatric patients with aHUS, and adult patients with gMG, supplemental dosing of EPYSQLI is required in the setting of concomitant plasmapheresis or plasma exchange, or fresh frozen plasma infusion (PE/PI) (<linkHtml href="#t2">Table 2</linkHtml>).</content>
                        </paragraph>
                        <table ID="t2" width="100%">
                           <caption>Table 2: Supplemental Dose of EPYSQLI after PE/PI</caption>
                           <col width="25.000%" align="left"/>
                           <col width="25.000%" align="left"/>
                           <col width="25.000%" align="left"/>
                           <col width="25.000%" align="left"/>
                           <tbody>
                              <tr>
                                 <td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule">
                                    <content styleCode="bold">Type of Plasma Intervention</content>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">Most Recent EPYSQLI Dose</content>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">Supplemental EPYSQLI Dose with Each Plasma Intervention</content>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">Timing of Supplemental EPYSQLI Dose</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2" align="left" valign="middle" styleCode="Botrule Lrule Rrule">Plasmapheresis or plasma exchange</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">300 mg</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">300 mg per each plasmapheresis or plasma exchange session</td>
                                 <td rowspan="2" align="center" valign="middle" styleCode="Botrule Rrule">Within 60 minutes after each plasmapheresis or plasma exchange</td>
                              </tr>
                              <tr>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">â¥600 mg</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">600 mg per each plasmapheresis or plasma exchange session</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">Fresh frozen plasma infusion</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">â¥300 mg</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">300 mg per infusion of fresh frozen plasma</td>
                                 <td align="center" valign="middle" styleCode="Botrule Rrule">60 minutes prior to each infusion of fresh frozen plasma</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250402"/>
                  </section>
               </component>
               <component>
                  <section ID="s13">
                     <id root="70a6ca34-fb4e-4d7a-90f1-4efe4a7d3801"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.6 Preparation</title>
                     <text>
                        <paragraph>Dilute EPYSQLI to a final admixture concentration of 5 mg/mL using the following steps:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Withdraw the required amount of EPYSQLI from the vial into a sterile syringe.</item>
                           <item>Transfer the recommended dose to an infusion bag.</item>
                           <item>Dilute EPYSQLI to a final concentration of 5 mg/mL by adding the appropriate amount (equal volume of diluent to drug volume) of 0.9% Sodium Chloride Injection, USP; 0.45% Sodium Chloride Injection, USP; or 5% Dextrose in Water Injection, USP to the infusion bag.</item>
                        </list>
                        <paragraph>The final admixed EPYSQLI 5 mg/mL infusion volume is 60 mL for 300 mg doses, 120 mL for 600 mg doses, 180 mL for 900 mg doses or 240 mL for 1,200 mg doses (<linkHtml href="#t3">Table 3</linkHtml>).</paragraph>
                        <table ID="t3" width="100%">
                           <caption>Table 3: Preparation and Reconstitution of EPYSQLI</caption>
                           <col width="33.311%" align="left"/>
                           <col width="33.344%" align="left"/>
                           <col width="33.344%" align="left"/>
                           <tbody>
                              <tr>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                                    <content styleCode="bold">EPYSQLI Dose</content>
                                 </td>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">Diluent Volume</content>
                                 </td>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">Final Volume</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="top" styleCode="Botrule Lrule Rrule">300 mg</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">30 mL</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">60 mL</td>
                              </tr>
                              <tr>
                                 <td align="center" valign="top" styleCode="Botrule Lrule Rrule">600 mg</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">60 mL</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">120 mL</td>
                              </tr>
                              <tr>
                                 <td align="center" valign="top" styleCode="Botrule Lrule Rrule">900 mg</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">90 mL</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">180 mL</td>
                              </tr>
                              <tr>
                                 <td align="center" valign="top" styleCode="Botrule Lrule Rrule">1,200 mg</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">120 mL</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">240 mL</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Gently invert the infusion bag containing the diluted EPYSQLI solution to ensure thorough mixing of the product and diluent. Discard any unused portion left in a vial, as the product contains no preservatives.</paragraph>
                        <paragraph>Prior to administration, the admixture should be allowed to adjust to room temperature [18Â°C to 25Â°C (64Â°F to 77Â°F)]. The admixture must not be heated in a microwave or with any heat source other than ambient air temperature.</paragraph>
                        <paragraph>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</paragraph>
                     </text>
                     <effectiveTime value="20250402"/>
                  </section>
               </component>
               <component>
                  <section ID="s14">
                     <id root="79a4390c-f34c-453c-8550-0c922bb0a93d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.7 Administration</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Only administer as an intravenous infusion.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Do not administer as an intravenous push or bolus injection.</content>
                        </paragraph>
                        <paragraph>Administer the EPYSQLI admixture by intravenous infusion over 35 minutes in adults and 1 to 4 hours in pediatric patients via gravity feed, a syringe-type pump, or an infusion pump. Admixed solutions of EPYSQLI are stable for 24 hours refrigerated at 2Â°C to 8Â°C (36Â°F to 46Â°F) and at room temperature.</paragraph>
                        <paragraph>If an adverse reaction occurs during the administration of EPYSQLI, the infusion may be slowed or stopped at the discretion of the physician. If the infusion is slowed, the total infusion time should not exceed two hours in adults. Monitor the patient for at least one hour following completion of the infusion for signs or symptoms of an infusion-related reaction.</paragraph>
                     </text>
                     <effectiveTime value="20250402"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s15">
               <id root="5432bc04-d259-4d09-a27b-435160992008"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3  DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Injection: 300 mg/30 mL (10 mg/mL) as a clear to slightly opalescent, and colorless solution in a single-dose vial.</paragraph>
               </text>
               <effectiveTime value="20250402"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Injection: 300 mg/30 mL (10 mg/mL)  in a single-dose vial. (<linkHtml href="#s15">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s16">
               <id root="2d8c5628-9551-4106-a2cc-4a54a151c90f"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4  CONTRAINDICATIONS</title>
               <text>
                  <paragraph>EPYSQLI is contraindicated for initiation in patients with unresolved serious <content styleCode="italics">Neisseria meningitidis</content> infection [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#s18">5.1</linkHtml>)</content>].</paragraph>
               </text>
               <effectiveTime value="20250402"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>EPYSQLI is contraindicated for initiation in patients with unresolved serious <content styleCode="italics">Neisseria meningitidis</content> infection. (<linkHtml href="#s16">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s17">
               <id root="8983aabb-95a7-4b25-871c-e89db6abb825"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5  WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250402"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Use caution when administering EPYSQLI to patients with any other systemic infection. (<linkHtml href="#s20">5.3</linkHtml>)</item>
                           <item>Infusion-Related Reactions: Monitor patients during infusion, interrupt for reactions, and institute appropriate supportive measures. (<linkHtml href="#s25">5.6</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s18">
                     <id root="022a0fcc-5bed-4875-813f-155393efae6d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1  Serious Meningococcal Infections</title>
                     <text>
                        <paragraph>Eculizumab products, complement inhibitors, increase a patient's susceptibility to serious, life-threatening, or fatal infections caused by meningococcal bacteria (septicemia and/or meningitis) in any serogroup, including non-groupable strains. Life-threatening and fatal meningococcal infections have occurred in both vaccinated and unvaccinated patients treated with complement inhibitors. . The initiation of EPYSQLI treatment is contraindicated in patients with unresolved serious <content styleCode="italics">Neisseria meningitidis</content> infection.</paragraph>
                        <paragraph>Complete or update meningococcal vaccination (for serogroups A, C, W, Y, and B) at least 2 weeks prior to administration of the first dose of EPYSQLI, according to current ACIP recommendations for patients receiving a complement inhibitor. Revaccinate patients in accordance with ACIP recommendations, considering the duration of  therapy with EPYSQLI. Note that ACIP recommends an administration schedule in patients receiving complement inhibitors that differs from the administration schedule in the vaccine prescribing information. If urgent EPYSQLI therapy is indicated in a patient who is not up to date with meningococcal vaccines according to ACIP recommendations, provide the patient with antibacterial drug prophylaxis and administer meningococcal vaccines as soon as possible. Various durations and regimens of antibacterial drug prophylaxis have been considered, but the optimal durations and drug regimens for prophylaxis and their efficacy have not been studied in unvaccinated or vaccinated patients receiving complement inhibitors, including eculizumab products. The benefits and risks of treatment with EPYSQLI, as well as the benefits and risks of antibacterial drug prophylaxis in unvaccinated or vaccinated patients, must be considered against the known risks for serious infections caused by <content styleCode="italics">Neisseria meningitidis</content>.</paragraph>
                        <paragraph>Vaccination does not eliminate the risk of serious meningococcal infections, despite development of antibodies following vaccination.</paragraph>
                        <paragraph>Closely monitor patients for early signs and symptoms of meningococcal infection and evaluate patients immediately if infection is suspected. Inform patients of these signs and symptoms and instruct patients to seek immediate medical care if these signs and symptoms occur. Promptly treat known infections. Meningococcal infection may become rapidly life- threatening or fatal if not recognized and treated early. Consider interruption of EPYSQLI in patients who are undergoing treatment for serious meningococcal infection, depending on the risks of interrupting treatment in the disease being treated.</paragraph>
                        <paragraph>EPYSQLI is available only through a restricted program under a REMS <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s19">5.2</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250402"/>
                  </section>
               </component>
               <component>
                  <section ID="s19">
                     <id root="c7898bf9-54d8-4f1e-9169-d5b08136161b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2  EPYSQLI REMS</title>
                     <text>
                        <paragraph>EPYSQLI is available only through a restricted program under a REMS called EPYSQLI REMS, because of the risk of serious meningococcal infections <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s18">5.1</linkHtml>)]</content>.</paragraph>
                        <paragraph>Notable requirements of the EPYSQLI REMS include the following:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Prescribers must enroll in the REMS.</item>
                           <item>Prescribers must counsel patients about the risk of serious meningococcal infection.</item>
                           <item>Prescribers must provide the patients with the REMS educational materials.</item>
                           <item>Prescribers must assess patient vaccination status for meningococcal vaccines (against serogroups A, C, W, Y and B) and vaccinate if needed according to current ACIP recommendations two weeks prior to the first dose of EPYSQLI.</item>
                           <item>Prescribers must provide a prescription for antibacterial drug prophylaxis if treatment must be started urgently and the patient is not up to date with meningococcal vaccines according to current ACIP recommendations at least two weeks prior to the first dose of EPYSQLI.</item>
                           <item>Healthcare settings and pharmacies that dispense EPYSQLI must be certified in the REMS and must verify prescribers are certified.</item>
                           <item>Patients must receive counseling from the prescriber about the need to receive meningococcal vaccines per ACIP recommendations, the need to take antibiotics as directed by the prescriber,  and the signs and symptoms of meningococcal infection.</item>
                           <item>Patients must be instructed to carry the Patient Safety Card with them at all times during and for 3 months following treatment with EPYSQLI.</item>
                        </list>
                        <paragraph>Further information is available at www.EPYSQLIREMS.com or 1-866-318-0342.</paragraph>
                     </text>
                     <effectiveTime value="20250402"/>
                  </section>
               </component>
               <component>
                  <section ID="s20">
                     <id root="382898d4-ab4a-40e1-bae7-2680ebc9d3e3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3  Other Infections</title>
                     <text>
                        <paragraph>Serious infections with <content styleCode="italics">Neisseria</content> species (other than <content styleCode="italics">Neisseria meningitidis</content>), including disseminated gonococcal infections, have been reported.</paragraph>
                        <paragraph>Eculizumab products block terminal complement activation; therefore, patients may have increased susceptibility to infections, especially with encapsulated bacteria, such as infections with <content styleCode="italics">Neisseria meningitidis</content> but also <content styleCode="italics">Streptococcus pneumoniae</content>, <content styleCode="italics">Haemophilus influenzae</content>, and to a lesser extent, <content styleCode="italics">Neisseria gonorrhoeae</content>. Additionally, <content styleCode="italics">Aspergillus</content> infections have occurred in immunocompromised and neutropenic patients. Children treated with eculizumab products may be at increased risk of developing serious infections due to <content styleCode="italics">Streptococcus pneumoniae</content> and <content styleCode="italics">Haemophilus influenzae</content> type b (Hib). Administer vaccinations for the prevention of <content styleCode="italics">Streptococcus pneumoniae</content> and <content styleCode="italics">Haemophilus influenzae</content> type b (Hib) infections according to ACIP recommendations. Patients receiving eculizumab products are at increased risk for infections due to these organisms, even if they develop antibodies following vaccination.</paragraph>
                     </text>
                     <effectiveTime value="20250402"/>
                  </section>
               </component>
               <component>
                  <section ID="s21">
                     <id root="fedf37d0-9e1d-4bc0-a066-7dc44cda9438"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Monitoring Disease Manifestations after EPYSQLI Discontinuation</title>
                     <effectiveTime value="20250402"/>
                     <component>
                        <section ID="s22">
                           <id root="72e017b4-67d4-49a2-a1d0-7329b239ff5d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Treatment Discontinuation for PNH</content>
                              </paragraph>
                              <paragraph>Monitor patients after discontinuing EPYSQLI for at least 8 weeks to detect hemolysis.</paragraph>
                           </text>
                           <effectiveTime value="20250402"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s23">
                           <id root="bc3e850a-f71b-4267-ba53-1148db4568ea"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Treatment Discontinuation for aHUS</content>
                              </paragraph>
                              <paragraph>After discontinuing EPYSQLI, monitor patients with aHUS for signs and symptoms of thrombotic microangiopathy (TMA) complications for at least 12 weeks. In aHUS clinical trials, 18 patients (5 in the prospective studies) discontinued eculizumab treatment. TMA complications occurred following a missed dose in 5 patients, and eculizumab was reinitiated in 4 of these 5 patients.</paragraph>
                              <paragraph>Clinical signs and symptoms of TMA include changes in mental status, seizures, angina, dyspnea, or thrombosis. In addition, the following changes in laboratory parameters may identify a TMA complication: occurrence of two, or repeated measurement of any one of the following: a decrease in platelet count by 25% or more compared to baseline or the peak platelet count during EPYSQLI treatment; an increase in serum creatinine by 25% or more compared to baseline or nadir during EPYSQLI treatment; or, an increase in serum LDH by 25% or more over baseline or nadir during EPYSQLI treatment.</paragraph>
                              <paragraph>If TMA complications occur after EPYSQLI discontinuation, consider reinstitution of EPYSQLI treatment, plasma therapy [plasmapheresis, plasma exchange, or fresh frozen plasma infusion (PE/PI)], or appropriate organ-specific supportive measures.</paragraph>
                           </text>
                           <effectiveTime value="20250402"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s24">
                     <id root="63aefb09-3d27-4e4d-9432-73fa84c317ea"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Thrombosis Prevention and Management</title>
                     <text>
                        <paragraph>The effect of withdrawal of anticoagulant therapy during eculizumab products treatment has not been established. Therefore, treatment with eculizumab products should not alter anticoagulant management.</paragraph>
                     </text>
                     <effectiveTime value="20250402"/>
                  </section>
               </component>
               <component>
                  <section ID="s25">
                     <id root="21efff60-7085-461c-9c83-1c1124190437"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Infusion-Related Reactions</title>
                     <text>
                        <paragraph>Administration of eculizumab products may result in infusion-related reactions, including anaphylaxis or other hypersensitivity reactions. In clinical trials, no patients experienced an infusion-related reaction which required discontinuation of eculizumab. Interrupt EPYSQLI infusion and institute appropriate supportive measures if signs of cardiovascular instability or respiratory compromise occur.</paragraph>
                     </text>
                     <effectiveTime value="20250402"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s26">
               <id root="8cb9b72d-73dc-43cd-acb6-b4dd3ca9066e"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6  ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following serious adverse reactions are discussed in greater detail in other sections of the labeling:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Serious Meningococcal Infections [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#s18">5.1</linkHtml>)</content>]</item>
                     <item>Other Infections [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#s20">5.3</linkHtml>)</content>]</item>
                     <item>Monitoring Disease Manifestations after EPYSQLI Discontinuation [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#s21">5.4</linkHtml>)</content>]</item>
                     <item>Thrombosis Prevention and Management [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#s24">5.5</linkHtml>)</content>]</item>
                     <item>Infusion-Related Reactions [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#s25">5.6</linkHtml>)</content>]</item>
                  </list>
               </text>
               <effectiveTime value="20250402"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most frequently reported adverse reactions in the PNH randomized trial (â¥10% overall and greater than placebo) are: headache, nasopharyngitis, back pain, and nausea.  (<linkHtml href="#s27">6.1</linkHtml>)</paragraph>
                        <paragraph>The most frequently reported adverse reactions in aHUS single arm prospective trials (â¥20%) are: headache, diarrhea, hypertension, upper respiratory infection, abdominal pain, vomiting, nasopharyngitis, anemia, cough, peripheral edema, nausea, urinary tract infections, pyrexia. (<linkHtml href="#s27">6.1</linkHtml>)</paragraph>
                        <paragraph>The most frequently reported adverse reaction in the gMG placebo-controlled clinical trial (â¥10%) is: musculoskeletal pain. (<linkHtml href="#s27">6.1</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Teva Pharmaceuticals at 1-888-483-8279 or FDA at 1-800-FDA-1088 or </content>
                           <content styleCode="underline bold">www.fda.gov/medwatch</content>
                           <content styleCode="bold">.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s27">
                     <id root="6509433b-de64-4bb3-a5f5-a8b1edd43f0d"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1  Clinical Trial Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>Meningococcal infections are the most important adverse reactions experienced by patients receiving eculizumab. In PNH clinical studies, two patients experienced meningococcal sepsis. Both patients had previously received a meningococcal vaccine. In clinical studies among patients without PNH, meningococcal meningitis occurred in one unvaccinated patient. Meningococcal sepsis occurred in one previously vaccinated patient enrolled in the retrospective aHUS study during the post-study follow-up period [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#s18">5.1</linkHtml>)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20250402"/>
                     <component>
                        <section ID="s28">
                           <id root="fc930fd2-b7d9-4dfa-aaaf-b6eb94bbc1ef"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">PNH</content>
                              </paragraph>
                              <paragraph>The data described below reflect exposure to eculizumab in 196 adult patients with PNH, age 18-85, of whom 55% were female. All had signs or symptoms of intravascular hemolysis. Eculizumab was studied in a placebo-controlled clinical study (PNH Study 1, in which 43 patients received eculizumab and 44, placebo); a single arm clinical study (PNH Study 2); and a long term extension study (E05-001). 182 patients were exposed for greater than one year. All patients received the recommended eculizumab dose regimen.</paragraph>
                              <paragraph>
                                 <linkHtml href="#t4">Table 4</linkHtml> summarizes the adverse reactions that occurred at a numerically higher rate in the eculizumab group than the placebo group and at a rate of 5% or more among patients treated with eculizumab.</paragraph>
                              <table ID="t4" width="100%" styleCode="Noautorules">
                                 <caption>Table 4: Adverse Reactions Reported in 5% or More of Eculizumab Treated Patients with PNH and Greater than Placebo in the Controlled Clinical Study</caption>
                                 <col width="39.913%" align="left"/>
                                 <col width="34.045%" align="left"/>
                                 <col width="26.042%" align="left"/>
                                 <thead>
                                    <tr>
                                       <th rowspan="3" align="left" valign="top" styleCode="Botrule">
                                          <content styleCode="bold">Reaction</content>
                                       </th>
                                       <th align="center" valign="top">
                                          <content styleCode="bold">Eculizumab</content>
                                       </th>
                                       <th align="center" valign="top">
                                          <content styleCode="bold">Placebo</content>
                                       </th>
                                    </tr>
                                    <tr>
                                       <th align="center" valign="top">
                                          <content styleCode="bold">(N=43)</content>
                                       </th>
                                       <th align="center" valign="top">
                                          <content styleCode="bold">(N=44)</content>
                                       </th>
                                    </tr>
                                    <tr>
                                       <th align="center" valign="top" styleCode="Botrule">
                                          <content styleCode="bold">N (%)</content>
                                       </th>
                                       <th align="center" valign="top" styleCode="Botrule">
                                          <content styleCode="bold">N (%)</content>
                                       </th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr>
                                       <td align="left" valign="top">Headache</td>
                                       <td align="center" valign="top">19 (44)</td>
                                       <td align="center" valign="top">12 (27)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">Nasopharyngitis</td>
                                       <td align="center" valign="top">10 (23)</td>
                                       <td align="center" valign="top">8 (18)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">Back pain</td>
                                       <td align="center" valign="top">8 (19)</td>
                                       <td align="center" valign="top">4 (9)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">Nausea</td>
                                       <td align="center" valign="top">7 (16)</td>
                                       <td align="center" valign="top">5 (11)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">Fatigue</td>
                                       <td align="center" valign="top">5 (12)</td>
                                       <td align="center" valign="top">1 (2)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">Cough</td>
                                       <td align="center" valign="top">5 (12)</td>
                                       <td align="center" valign="top">4 (9)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">Herpes simplex infections</td>
                                       <td align="center" valign="top">3 (7)</td>
                                       <td align="center" valign="top">0</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">Sinusitis</td>
                                       <td align="center" valign="top">3 (7)</td>
                                       <td align="center" valign="top">0</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">Respiratory tract infection</td>
                                       <td align="center" valign="top">3 (7)</td>
                                       <td align="center" valign="top">1 (2)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">Constipation</td>
                                       <td align="center" valign="top">3 (7)</td>
                                       <td align="center" valign="top">2 (5)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">Myalgia</td>
                                       <td align="center" valign="top">3 (7)</td>
                                       <td align="center" valign="top">1 (2)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">Pain in extremity</td>
                                       <td align="center" valign="top">3 (7)</td>
                                       <td align="center" valign="top">1 (2)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">Influenza-like illness</td>
                                       <td align="center" valign="top">2 (5)</td>
                                       <td align="center" valign="top">1 (2)</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>In the placebo-controlled clinical study, serious adverse reactions occurred among 4 (9%) patients receiving eculizumab and 9 (21%) patients receiving placebo. The serious reactions included infections and progression of PNH. No deaths occurred in the study and no patients receiving eculizumab experienced a thrombotic event; one thrombotic event occurred in a patient receiving placebo.</paragraph>
                              <paragraph>Among 193 patients with PNH treated with eculizumab in the single arm, clinical study or the follow-up study, the adverse reactions were similar to those reported in the placebo-controlled clinical study. Serious adverse reactions occurred among 16% of the patients in these studies. The most common serious adverse reactions were: viral infection (2%), headache (2%), anemia (2%), and pyrexia (2%).</paragraph>
                           </text>
                           <effectiveTime value="20250402"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s29">
                           <id root="90a9abd5-9f65-46eb-9839-f266c3742b6e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">aHUS</content>
                              </paragraph>
                              <paragraph>The safety of eculizumab therapy in patients with aHUS was evaluated in four prospective, single-arm studies, three in adult and adolescent patients (Studies C08-002A/B, C08-003A/B, and C10-004), one in pediatric and adolescent patients (Study C10-003), and one retrospective study (Study C09-001r).</paragraph>
                              <paragraph>The data described below were derived from 78 adult and adolescent patients with aHUS in Studies C08-002A/B, C08-003A/B and C10-004. All patients received the recommended dosage of eculizumab. Median exposure was 67 weeks (range: 2-145 weeks). <linkHtml href="#t5">Table 5</linkHtml> summarizes all adverse events reported in at least 10% of patients in Studies C08-002A/B, C08-003A/B and C10-004 combined.</paragraph>
                              <table ID="t5" width="100%" styleCode="Noautorules">
                                 <caption>Table 5: Per Patient Incidence of Adverse Events in 10% or More Adult and Adolescent Patients Enrolled in Studies C08-002A/B, C08-003A/B and C10-004 Separately and in Total</caption>
                                 <col width="60.620%" align="left"/>
                                 <col width="11.480%" align="left"/>
                                 <col width="11.480%" align="left"/>
                                 <col width="8.740%" align="left"/>
                                 <col width="7.680%" align="left"/>
                                 <thead>
                                    <tr>
                                       <th align="left" valign="top"/>
                                       <th colspan="4" align="center" valign="middle">
                                          <content styleCode="bold">Number (%) of Patients</content>
                                       </th>
                                    </tr>
                                    <tr>
                                       <th align="left" valign="top"/>
                                       <th align="center" valign="middle">
                                          <content styleCode="bold">C08-002A/B</content>
                                       </th>
                                       <th align="center" valign="middle">
                                          <content styleCode="bold">C08-003A/B</content>
                                       </th>
                                       <th align="center" valign="middle">
                                          <content styleCode="bold">C10-004</content>
                                       </th>
                                       <th align="center" valign="middle">
                                          <content styleCode="bold">Total</content>
                                       </th>
                                    </tr>
                                    <tr>
                                       <th align="left" valign="top" styleCode="Botrule"/>
                                       <th align="center" valign="middle" styleCode="Botrule">
                                          <content styleCode="bold">(N=17)</content>
                                       </th>
                                       <th align="center" valign="middle" styleCode="Botrule">
                                          <content styleCode="bold">(N=20)</content>
                                       </th>
                                       <th align="center" valign="middle" styleCode="Botrule">
                                          <content styleCode="bold">(N=41)</content>
                                       </th>
                                       <th align="center" valign="middle" styleCode="Botrule">
                                          <content styleCode="bold">(N=78)</content>
                                       </th>
                                    </tr>
                                 </thead>
                                 <tfoot>
                                    <tr>
                                       <td colspan="5" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>a.</sup> includes the preferred terms hypertension, accelerated hypertension, and malignant hypertension.</paragraph>
                                       </td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td align="left" valign="top">
                                          <content styleCode="bold">Vascular Disorders</content>
                                       </td>
                                       <td align="center" valign="middle"/>
                                       <td align="center" valign="middle"/>
                                       <td align="center" valign="middle"/>
                                       <td align="center" valign="middle"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">Â  Â  Â Hypertension<sup>a</sup>
                                       </td>
                                       <td align="center" valign="middle">10 (59)</td>
                                       <td align="center" valign="middle">9 (45)</td>
                                       <td align="center" valign="middle">7 (17)</td>
                                       <td align="center" valign="middle">26 (33)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">Â  Â  Â Hypotension</td>
                                       <td align="center" valign="middle">2 (12)</td>
                                       <td align="center" valign="middle">4 (20)</td>
                                       <td align="center" valign="middle">7 (17)</td>
                                       <td align="center" valign="middle">13 (17)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">
                                          <content styleCode="bold">Infections and Infestations</content>
                                       </td>
                                       <td align="center" valign="middle"/>
                                       <td align="center" valign="middle"/>
                                       <td align="center" valign="middle"/>
                                       <td align="center" valign="middle"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">Â  Â  Â Bronchitis</td>
                                       <td align="center" valign="middle">3 (18)</td>
                                       <td align="center" valign="middle">2 (10)</td>
                                       <td align="center" valign="middle">4 (10)</td>
                                       <td align="center" valign="middle">9 (12)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">Â  Â  Â Nasopharyngitis</td>
                                       <td align="center" valign="middle">3 (18)</td>
                                       <td align="center" valign="middle">11 (55)</td>
                                       <td align="center" valign="middle">7 (17)</td>
                                       <td align="center" valign="middle">21 (27)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">Â  Â  Â Gastroenteritis</td>
                                       <td align="center" valign="middle">3 (18)</td>
                                       <td align="center" valign="middle">4 (20)</td>
                                       <td align="center" valign="middle">2 (5)</td>
                                       <td align="center" valign="middle">9 (12)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">Â  Â  Â Upper respiratory tract infection</td>
                                       <td align="center" valign="middle">5 (29)</td>
                                       <td align="center" valign="middle">8 (40)</td>
                                       <td align="center" valign="middle">2 (5)</td>
                                       <td align="center" valign="middle">15 (19)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">Â  Â  Â Urinary tract infection</td>
                                       <td align="center" valign="middle">6 (35)</td>
                                       <td align="center" valign="middle">3 (15)</td>
                                       <td align="center" valign="middle">8 (20)</td>
                                       <td align="center" valign="middle">17 (22)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">
                                          <content styleCode="bold">Gastrointestinal Disorders</content>
                                       </td>
                                       <td align="center" valign="middle"/>
                                       <td align="center" valign="middle"/>
                                       <td align="center" valign="middle"/>
                                       <td align="center" valign="middle"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">Â  Â  Â Diarrhea</td>
                                       <td align="center" valign="middle">8 (47)</td>
                                       <td align="center" valign="middle">8 (40)</td>
                                       <td align="center" valign="middle">12 (32)</td>
                                       <td align="center" valign="middle">29 (37)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">Â  Â  Â Vomiting</td>
                                       <td align="center" valign="middle">8 (47)</td>
                                       <td align="center" valign="middle">9 (45)</td>
                                       <td align="center" valign="middle">6 (15)</td>
                                       <td align="center" valign="middle">23 (30)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">Â  Â  Â Nausea</td>
                                       <td align="center" valign="middle">5 (29)</td>
                                       <td align="center" valign="middle">8 (40)</td>
                                       <td align="center" valign="middle">5 (12)</td>
                                       <td align="center" valign="middle">18 (23)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">Â  Â  Â Abdominal pain</td>
                                       <td align="center" valign="top">3 (18)</td>
                                       <td align="center" valign="top">6 (30)</td>
                                       <td align="center" valign="top">6 (15)</td>
                                       <td align="center" valign="top">15 (19)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">
                                          <content styleCode="bold">Nervous System Disorders</content>
                                       </td>
                                       <td align="center" valign="top"/>
                                       <td align="center" valign="top"/>
                                       <td align="center" valign="top"/>
                                       <td align="center" valign="top"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">Â  Â  Â Headache</td>
                                       <td align="center" valign="top">7 (41)</td>
                                       <td align="center" valign="top">10 (50)</td>
                                       <td align="center" valign="top">15 (37)</td>
                                       <td align="center" valign="top">32 (41)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">
                                          <content styleCode="bold">Blood and Lymphatic System Disorders</content>
                                       </td>
                                       <td align="center" valign="top"/>
                                       <td align="center" valign="top"/>
                                       <td align="center" valign="top"/>
                                       <td align="center" valign="top"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">Â  Â  Â Anemia</td>
                                       <td align="center" valign="top">6 (35)</td>
                                       <td align="center" valign="top">7 (35)</td>
                                       <td align="center" valign="top">7 (17)</td>
                                       <td align="center" valign="top">20 (26)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">Â  Â  Â Leukopenia</td>
                                       <td align="center" valign="top">4 (24)</td>
                                       <td align="center" valign="top">3 (15)</td>
                                       <td align="center" valign="top">5 (12)</td>
                                       <td align="center" valign="top">12 (15)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">
                                          <content styleCode="bold">Psychiatric Disorders</content>
                                       </td>
                                       <td align="center" valign="top"/>
                                       <td align="center" valign="top"/>
                                       <td align="center" valign="top"/>
                                       <td align="center" valign="top"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">Â  Â  Â Insomnia</td>
                                       <td align="center" valign="top">4 (24)</td>
                                       <td align="center" valign="top">2 (10)</td>
                                       <td align="center" valign="top">5 (12)</td>
                                       <td align="center" valign="top">11 (14)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">
                                          <content styleCode="bold">Renal and Urinary Disorders</content>
                                       </td>
                                       <td align="center" valign="top"/>
                                       <td align="center" valign="top"/>
                                       <td align="center" valign="top"/>
                                       <td align="center" valign="top"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">Â  Â  Â Renal Impairment</td>
                                       <td align="center" valign="top">5 (29)</td>
                                       <td align="center" valign="top">3 (15)</td>
                                       <td align="center" valign="top">6 (15)</td>
                                       <td align="center" valign="top">14 (18)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">Â  Â  Â Proteinuria</td>
                                       <td align="center" valign="top">2 (12)</td>
                                       <td align="center" valign="top">1 (5)</td>
                                       <td align="center" valign="top">5 (12)</td>
                                       <td align="center" valign="top">8 (10)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">
                                          <content styleCode="bold">Respiratory, Thoracic and Mediastinal Disorders</content>
                                       </td>
                                       <td align="center" valign="top"/>
                                       <td align="center" valign="top"/>
                                       <td align="center" valign="top"/>
                                       <td align="center" valign="top"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">Â  Â  Â Cough</td>
                                       <td align="center" valign="top">4 (24)</td>
                                       <td align="center" valign="top">6 (30)</td>
                                       <td align="center" valign="top">8 (20)</td>
                                       <td align="center" valign="top">18 (23)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">
                                          <content styleCode="bold">General Disorders and Administration Site Conditions</content>
                                       </td>
                                       <td align="center" valign="top"/>
                                       <td align="center" valign="top"/>
                                       <td align="center" valign="top"/>
                                       <td align="center" valign="top"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">Â  Â  Â Fatigue</td>
                                       <td align="center" valign="top">3 (18)</td>
                                       <td align="center" valign="top">4 (20)</td>
                                       <td align="center" valign="top">3 (7)</td>
                                       <td align="center" valign="top">10 (13)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">Â  Â  Â Peripheral edema</td>
                                       <td align="center" valign="top">5 (29)</td>
                                       <td align="center" valign="top">4 (20)</td>
                                       <td align="center" valign="top">9 (22)</td>
                                       <td align="center" valign="top">18 (23)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">Â  Â  Â Pyrexia</td>
                                       <td align="center" valign="top">4 (24)</td>
                                       <td align="center" valign="top">5 (25)</td>
                                       <td align="center" valign="top">7 (17)</td>
                                       <td align="center" valign="top">16 (21)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">Â  Â  Â Asthenia</td>
                                       <td align="center" valign="top">3 (18)</td>
                                       <td align="center" valign="top">4 (20)</td>
                                       <td align="center" valign="top">6 (15)</td>
                                       <td align="center" valign="top">13 (17)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">
                                          <content styleCode="bold">Eye Disorder</content>
                                       </td>
                                       <td align="center" valign="top">5 (29)</td>
                                       <td align="center" valign="top">2 (10)</td>
                                       <td align="center" valign="top">8 (20)</td>
                                       <td align="center" valign="top">15 (19)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">
                                          <content styleCode="bold">Metabolism and Nutrition Disorders</content>
                                       </td>
                                       <td align="center" valign="top"/>
                                       <td align="center" valign="top"/>
                                       <td align="center" valign="top"/>
                                       <td align="center" valign="top"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">Â  Â  Â Hypokalemia</td>
                                       <td align="center" valign="top">3 (18)</td>
                                       <td align="center" valign="top">2 (10)</td>
                                       <td align="center" valign="top">4 (10)</td>
                                       <td align="center" valign="top">9 (12)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">
                                          <content styleCode="bold">Neoplasms benign, malignant, and unspecified (including cysts and polyps)</content>
                                       </td>
                                       <td align="center" valign="middle">1 (6)</td>
                                       <td align="center" valign="middle">6 (30)</td>
                                       <td align="center" valign="middle">1 (20)</td>
                                       <td align="center" valign="middle">8 (10)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">
                                          <content styleCode="bold">Skin and Subcutaneous Tissue Disorders</content>
                                       </td>
                                       <td align="center" valign="top"/>
                                       <td align="center" valign="top"/>
                                       <td align="center" valign="top"/>
                                       <td align="center" valign="top"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">Â  Â  Â Rash</td>
                                       <td align="center" valign="top">2 (12)</td>
                                       <td align="center" valign="top">3 (15)</td>
                                       <td align="center" valign="top">6 (15)</td>
                                       <td align="center" valign="top">11 (14)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">Â  Â  Â Pruritus</td>
                                       <td align="center" valign="top">1 (6)</td>
                                       <td align="center" valign="top">3 (15)</td>
                                       <td align="center" valign="top">4 (10)</td>
                                       <td align="center" valign="top">8 (10)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">
                                          <content styleCode="bold">Musculoskeletal and Connective Tissue Disorders</content>
                                       </td>
                                       <td align="center" valign="top"/>
                                       <td align="center" valign="top"/>
                                       <td align="center" valign="top"/>
                                       <td align="center" valign="top"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">Â  Â  Â Arthralgia</td>
                                       <td align="center" valign="top">1 (6)</td>
                                       <td align="center" valign="top">2 (10)</td>
                                       <td align="center" valign="top">7 (17)</td>
                                       <td align="center" valign="top">10 (13)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule">Â  Â  Â Back pain</td>
                                       <td align="center" valign="top" styleCode="Botrule">3 (18)</td>
                                       <td align="center" valign="top" styleCode="Botrule">3 (15)</td>
                                       <td align="center" valign="top" styleCode="Botrule">2 (5)</td>
                                       <td align="center" valign="top" styleCode="Botrule">8 (10)</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>In Studies C08-002A/B, C08-003A/B and C10-004 combined, 60% (47/78) of patients experienced a serious adverse event (SAE). The most commonly reported SAEs were infections (24%), hypertension (5%), chronic renal failure (5%), and renal impairment (5%). Five patients discontinued eculizumab due to adverse events; three due to worsening renal function, one due to new diagnosis of Systemic Lupus Erythematosus, and one due to meningococcal meningitis.</paragraph>
                              <paragraph>Study C10-003 included 22 pediatric and adolescent patients, of which 18 patients were less than 12 years of age. All patients received the recommended dosage of eculizumab. Median exposure was 44 weeks (range: 1 dose-87 weeks).</paragraph>
                              <paragraph>
                                 <linkHtml href="#t6">Table 6</linkHtml> summarizes all adverse events reported in at least 10% of patients enrolled in Study C10-003.</paragraph>
                              <table ID="t6" width="100%" styleCode="Noautorules">
                                 <caption>Table 6: Per Patient Incidence of Adverse Reactions in 10% or More Patients Enrolled in Study C10-003</caption>
                                 <col width="38.067%" align="left"/>
                                 <col width="30.967%" align="left"/>
                                 <col width="30.967%" align="left"/>
                                 <thead>
                                    <tr>
                                       <th align="left" valign="top" styleCode="Botrule"/>
                                       <th align="center" valign="middle" styleCode="Botrule">
                                          <content styleCode="bold">1 month to &lt;12 yrs</content>
                                          <br/>
                                          <content styleCode="bold">(N=18)</content>
                                       </th>
                                       <th align="center" valign="middle" styleCode="Botrule">
                                          <content styleCode="bold">Total</content>
                                          <br/>
                                          <content styleCode="bold">(N=22)</content>
                                       </th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr>
                                       <td align="left" valign="middle">
                                          <content styleCode="bold">Eye Disorders</content>
                                       </td>
                                       <td align="center" valign="middle">3 (17)</td>
                                       <td align="center" valign="middle">3 (14)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">
                                          <content styleCode="bold">Gastrointestinal Disorders</content>
                                       </td>
                                       <td align="center" valign="middle"/>
                                       <td align="center" valign="middle"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">Â  Â  Â Abdominal pain</td>
                                       <td align="center" valign="middle">6 (33)</td>
                                       <td align="center" valign="middle">7 (32)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">Â  Â  Â Diarrhea</td>
                                       <td align="center" valign="middle">5 (28)</td>
                                       <td align="center" valign="middle">7 (32)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">Â  Â  Â Vomiting</td>
                                       <td align="center" valign="middle">4 (22)</td>
                                       <td align="center" valign="middle">6 (27)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">Â  Â  Â Dyspepsia</td>
                                       <td align="center" valign="middle">0</td>
                                       <td align="center" valign="middle">3 (14)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">
                                          <content styleCode="bold">General Disorders and Administration Site Conditions</content>
                                       </td>
                                       <td align="center" valign="middle"/>
                                       <td align="center" valign="middle"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">Â  Â  Â Pyrexia</td>
                                       <td align="center" valign="middle">9 (50)</td>
                                       <td align="center" valign="middle">11 (50)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">
                                          <content styleCode="bold">Infections and Infestations</content>
                                       </td>
                                       <td align="center" valign="middle"/>
                                       <td align="center" valign="middle"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">Â  Â  Â Upper respiratory tract infection</td>
                                       <td align="center" valign="middle">5 (28)</td>
                                       <td align="center" valign="middle">7 (32)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">Â  Â  Â Nasopharyngitis</td>
                                       <td align="center" valign="middle">3 (17)</td>
                                       <td align="center" valign="middle">6 (27)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">Â  Â  Â Rhinitis</td>
                                       <td align="center" valign="middle">4 (22)</td>
                                       <td align="center" valign="middle">4 (18)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">Â  Â  Â Urinary Tract infection</td>
                                       <td align="center" valign="middle">3 (17)</td>
                                       <td align="center" valign="middle">4 (18)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">Â  Â  Â Catheter site infection</td>
                                       <td align="center" valign="middle">3 (17)</td>
                                       <td align="center" valign="middle">3 (14)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">
                                          <content styleCode="bold">Musculoskeletal and Connective Tissue Disorders</content>
                                       </td>
                                       <td align="center" valign="middle"/>
                                       <td align="center" valign="middle"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">Â  Â  Â Muscle spasms</td>
                                       <td align="center" valign="middle">2 (11)</td>
                                       <td align="center" valign="middle">3 (14)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">
                                          <content styleCode="bold">Nervous System Disorders</content>
                                       </td>
                                       <td align="center" valign="middle"/>
                                       <td align="center" valign="middle"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">Â  Â  Â Headache</td>
                                       <td align="center" valign="middle">3 (17)</td>
                                       <td align="center" valign="middle">4 (18)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">
                                          <content styleCode="bold">Renal and Urinary Disorders</content>
                                       </td>
                                       <td align="center" valign="middle">3 (17)</td>
                                       <td align="center" valign="middle">4 (18)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">
                                          <content styleCode="bold">Respiratory, Thoracic and Mediastinal Disorders</content>
                                       </td>
                                       <td align="center" valign="middle"/>
                                       <td align="center" valign="middle"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">Â  Â  Â Cough</td>
                                       <td align="center" valign="middle">7 (39)</td>
                                       <td align="center" valign="middle">8 (36)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">Â  Â  Â Oropharyngeal pain</td>
                                       <td align="center" valign="middle">1 (6)</td>
                                       <td align="center" valign="middle">3 (14)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">
                                          <content styleCode="bold">Skin and Subcutaneous Tissue Disorders</content>
                                       </td>
                                       <td align="center" valign="middle"/>
                                       <td align="center" valign="middle"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">Â  Â  Â Rash</td>
                                       <td align="center" valign="middle">4 (22)</td>
                                       <td align="center" valign="middle">4 (18)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">
                                          <content styleCode="bold">Vascular Disorders</content>
                                       </td>
                                       <td align="center" valign="middle"/>
                                       <td align="center" valign="middle"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule">Â  Â  Â Hypertension</td>
                                       <td align="center" valign="middle" styleCode="Botrule">4 (22)</td>
                                       <td align="center" valign="middle" styleCode="Botrule">4 (18)</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>In Study C10-003, 59% (13/22) of patients experienced a serious adverse event (SAE). The most commonly reported SAEs were hypertension (9%), viral gastroenteritis (9%), pyrexia (9%), and upper respiratory infection (9%). One patient discontinued eculizumab due to an adverse event (severe agitation).</paragraph>
                              <paragraph>Analysis of retrospectively collected adverse event data from pediatric and adult patients enrolled in Study C09-001r (N=30) revealed a safety profile that was similar to that which was observed in the two prospective studies. Study C09-001r included 19 pediatric patients less than 18 years of age.</paragraph>
                              <paragraph>Overall, the safety of eculizumab in pediatric patients with aHUS enrolled in Study C09-001r appeared similar to that observed in adult patients. The most common (â¥15%) adverse events occurring in pediatric patients are presented in <linkHtml href="#t7">Table 7</linkHtml>.</paragraph>
                              <table ID="t7" width="100%" styleCode="Noautorules">
                                 <caption>Table 7: Adverse Reactions Occurring in at Least 15% of Patients Less than 18 Years of Age Enrolled in Study C09-001r</caption>
                                 <col width="34.367%" align="left"/>
                                 <col width="14.943%" align="left"/>
                                 <col width="17.303%" align="left"/>
                                 <col width="17.083%" align="left"/>
                                 <col width="16.303%" align="left"/>
                                 <thead>
                                    <tr>
                                       <th align="left" valign="top"/>
                                       <th colspan="4" align="center" valign="middle">
                                          <content styleCode="bold">Number (%) of Patients</content>
                                       </th>
                                    </tr>
                                    <tr>
                                       <th align="left" valign="top" styleCode="Botrule"/>
                                       <th align="center" valign="middle" styleCode="Botrule">
                                          <content styleCode="bold">&lt; 2 yrs</content>
                                          <br/>
                                          <content styleCode="bold">(N=5)</content>
                                       </th>
                                       <th align="center" valign="middle" styleCode="Botrule">
                                          <content styleCode="bold">2 to &lt; 12 yrs</content>
                                          <br/>
                                          <content styleCode="bold">(N=10)</content>
                                       </th>
                                       <th align="center" valign="middle" styleCode="Botrule">
                                          <content styleCode="bold">12 to &lt; 18 yrs</content>
                                          <br/>
                                          <content styleCode="bold">(N=4)</content>
                                       </th>
                                       <th align="center" valign="middle" styleCode="Botrule">
                                          <content styleCode="bold">Total</content>
                                          <br/>
                                          <content styleCode="bold">(N=19)</content>
                                       </th>
                                    </tr>
                                 </thead>
                                 <tfoot>
                                    <tr>
                                       <td colspan="5" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>a.</sup> includes the preferred terms upper respiratory tract infection and nasopharyngitis.</paragraph>
                                       </td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td align="left" valign="middle">
                                          <content styleCode="bold">General Disorders and Administration Site Conditions</content>
                                       </td>
                                       <td align="center" valign="middle"/>
                                       <td align="center" valign="middle"/>
                                       <td align="center" valign="middle"/>
                                       <td align="center" valign="middle"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">Â  Â  Â Pyrexia</td>
                                       <td align="center" valign="middle">4 (80)</td>
                                       <td align="center" valign="middle">4 (40)</td>
                                       <td align="center" valign="middle">1 (25)</td>
                                       <td align="center" valign="middle">9 (47)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">
                                          <content styleCode="bold">Gastrointestinal Disorders</content>
                                       </td>
                                       <td align="center" valign="middle"/>
                                       <td align="center" valign="middle"/>
                                       <td align="center" valign="middle"/>
                                       <td align="center" valign="middle"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">Â  Â  Â Diarrhea</td>
                                       <td align="center" valign="middle">1 (20)</td>
                                       <td align="center" valign="middle">4 (40)</td>
                                       <td align="center" valign="middle">1 (25)</td>
                                       <td align="center" valign="middle">6 (32)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">Â  Â  Â Vomiting</td>
                                       <td align="center" valign="middle">2 (40)</td>
                                       <td align="center" valign="middle">1 (10)</td>
                                       <td align="center" valign="middle">1 (25)</td>
                                       <td align="center" valign="middle">4 (21)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">
                                          <content styleCode="bold">Infections and Infestations</content>
                                       </td>
                                       <td align="center" valign="middle"/>
                                       <td align="center" valign="middle"/>
                                       <td align="center" valign="middle"/>
                                       <td align="center" valign="middle"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">Â  Â  Â Upper respiratory tract infection<sup>a</sup>
                                       </td>
                                       <td align="center" valign="middle">2 (40)</td>
                                       <td align="center" valign="middle">3 (30)</td>
                                       <td align="center" valign="middle">1 (25)</td>
                                       <td align="center" valign="middle">6 (32)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">
                                          <content styleCode="bold">Respiratory, Thoracic and Mediastinal Disorders</content>
                                       </td>
                                       <td align="center" valign="middle"/>
                                       <td align="center" valign="middle"/>
                                       <td align="center" valign="middle"/>
                                       <td align="center" valign="middle"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">Â  Â  Â Cough</td>
                                       <td align="center" valign="middle">3 (60)</td>
                                       <td align="center" valign="middle">2 (20)</td>
                                       <td align="center" valign="middle">0 (0)</td>
                                       <td align="center" valign="middle">5 (26)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">Â  Â  Â Nasal congestion</td>
                                       <td align="center" valign="middle">2 (40)</td>
                                       <td align="center" valign="middle">2 (20)</td>
                                       <td align="center" valign="middle">0 (0)</td>
                                       <td align="center" valign="middle">4 (21)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">
                                          <content styleCode="bold">Cardiac Disorders</content>
                                       </td>
                                       <td align="center" valign="middle"/>
                                       <td align="center" valign="middle"/>
                                       <td align="center" valign="middle"/>
                                       <td align="center" valign="middle"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">Â  Â  Â Tachycardia</td>
                                       <td align="center" valign="middle">2 (40)</td>
                                       <td align="center" valign="middle">2 (20)</td>
                                       <td align="center" valign="middle">0 (0)</td>
                                       <td align="center" valign="middle">4 (21)</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20250402"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s30">
                           <id root="1d482cd2-3d45-4fb5-bb56-e5c534bfcf8e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Generalized Myasthenia Gravis (gMG)</content>
                              </paragraph>
                              <paragraph>In a 26-week placebo-controlled trial evaluating the effect of eculizumab for the treatment of gMG (gMG Study 1), 62 patients received eculizumab at the recommended dosage regimen and 63 patients received placebo [see Clinical Studies (<linkHtml href="#s70">14.3</linkHtml>)]. Patients were 19 to 79 years of age, and 66% were female. <linkHtml href="#t8">Table 8</linkHtml> displays the most common adverse reactions from gMG Study 1 that occurred in â¥5% of eculizumab-treated patients and at a greater frequency than on placebo.</paragraph>
                              <table ID="t8" width="100%" styleCode="Noautorules">
                                 <caption>Table 8: Adverse Reactions Reported in 5% or More of Eculizumab-Treated Patients in gMG Study 1 and at a Greater Frequency than in Placebo-Treated Patients</caption>
                                 <col width="34.378%" align="left"/>
                                 <col width="32.244%" align="left"/>
                                 <col width="33.378%" align="left"/>
                                 <thead>
                                    <tr>
                                       <th align="left" valign="top" styleCode="Botrule"/>
                                       <th align="center" valign="middle" styleCode="Botrule">
                                          <content styleCode="bold">Eculizumab</content>
                                          <br/>
                                          <content styleCode="bold">(N=62)</content>
                                          <br/>
                                          <content styleCode="bold">N (%)</content>
                                       </th>
                                       <th align="center" valign="middle" styleCode="Botrule">
                                          <content styleCode="bold">Placebo</content>
                                          <br/>
                                          <content styleCode="bold">(N=63)</content>
                                          <br/>
                                          <content styleCode="bold">N (%)</content>
                                       </th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr>
                                       <td align="left" valign="middle">
                                          <content styleCode="bold">Gastrointestinal Disorders</content>
                                       </td>
                                       <td align="center" valign="middle"/>
                                       <td align="center" valign="middle"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">Â  Â  Â Abdominal pain<br/>
                                       </td>
                                       <td align="center" valign="middle">5 (8)</td>
                                       <td align="center" valign="middle">3 (5)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">
                                          <content styleCode="bold">General Disorders and Administration Site Conditions</content>
                                       </td>
                                       <td align="center" valign="middle"/>
                                       <td align="center" valign="middle"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">Â  Â  Â Peripheral edema</td>
                                       <td align="center" valign="middle">5 (8)</td>
                                       <td align="center" valign="middle">3 (5)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">Â  Â  Â Pyrexia</td>
                                       <td align="center" valign="middle">4 (7)</td>
                                       <td align="center" valign="middle">2 (3)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">
                                          <content styleCode="bold">Infections and Infestations</content>
                                          <br/>
                                       </td>
                                       <td align="center" valign="middle"/>
                                       <td align="center" valign="middle"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">Â  Â  Â Herpes simplex virus <br/>Â  Â  Â infections<br/>
                                          <br/>Herpes simplex virus infections<br/>
                                       </td>
                                       <td align="center" valign="middle">5 (8)</td>
                                       <td align="center" valign="middle">1 (2)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">
                                          <content styleCode="bold">Injury, Poisoning, and Procedural Complications</content>
                                       </td>
                                       <td align="center" valign="middle"/>
                                       <td align="center" valign="middle"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">Â  Â  Â Contusion</td>
                                       <td align="center" valign="middle">5 (8)</td>
                                       <td align="center" valign="middle">2 (3)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">
                                          <content styleCode="bold">Musculoskeletal and Connective Tissue Disorders</content>
                                       </td>
                                       <td align="center" valign="middle"/>
                                       <td align="center" valign="middle"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">Â  Â  Â Musculoskeletal pain</td>
                                       <td align="center" valign="middle">9 (15)</td>
                                       <td align="center" valign="middle">5 (8)</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>The most common adverse reactions (â¥10%) that occurred in eculizumab-treated patients in the long-term extension to gMG Study 1, Study ECU-MG-302, and that are not included in <linkHtml href="#t8">Table 8</linkHtml> were headache (26%), nasopharyngitis (24%), diarrhea (15%), arthralgia (12%), upper respiratory tract infection (11%), and nausea (10%).</paragraph>
                           </text>
                           <effectiveTime value="20250402"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s31">
                     <id root="e033936c-49bf-4686-bd59-b5caea51919b"/>
                     <code code="90375-7" codeSystem="2.16.840.1.113883.6.1" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post-approval use of eculizumab products. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to eculizumab products exposure.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Adverse Reactions from Postmarketing Spontaneous Reports</content>
                        </paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>Fatal or serious infections: <content styleCode="italics">Neisseria gonorrhoeae</content>, <content styleCode="italics">Neisseria meningitidis</content>, <content styleCode="italics">Neisseria sicca/subflava</content>, <content styleCode="italics">Neisseria spp</content> unspecified.</item>
                           <item>Cases of cholestatic or mixed pattern liver injury with increased serum liver enzymes and bilirubin levels have been reported in adult and pediatric patients with aHUS who were treated with eculizumab products. These events occurred within 3 to 27 days after starting treatment. The median time to resolution (or return to baseline) was approximately 3 weeks.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250402"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s32">
               <id root="f96bd53f-a9ac-4013-a7df-7751fd452739"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20250402"/>
               <component>
                  <section ID="s33">
                     <id root="9c778361-bfa4-4864-be47-af74921ff4eb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Plasmapheresis, Plasma Exchange, or Fresh Frozen Plasma Infusion</title>
                     <text>
                        <paragraph>Concomitant use of eculizumab products with plasma exchange (PE), plasmapheresis (PP) or fresh frozen plasma infusion (PE/PI) treatment can reduce serum eculizumab product  concentrations and requires a supplemental dose of EPYSQLI <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s12">2.5</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250402"/>
                  </section>
               </component>
               <component>
                  <section ID="s34">
                     <id root="16510b8f-0886-4a05-aaff-c79053d1c717"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Neonatal Fc Receptor Blockers</title>
                     <text>
                        <paragraph>Concomitant use of eculizumab products with neonatal Fc receptor (FcRn) blockers may lower systemic exposures and reduce effectiveness of eculizumab products. Closely monitor for reduced effectiveness of EPYSQLI.</paragraph>
                     </text>
                     <effectiveTime value="20250402"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s35">
               <id root="aabd3881-0db9-4e2f-9a81-d3260421d746"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8  USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250402"/>
               <component>
                  <section ID="s36">
                     <id root="29951299-def2-43fd-b4fc-a2e78bd62b29"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1  Pregnancy</title>
                     <effectiveTime value="20250402"/>
                     <component>
                        <section ID="s37">
                           <id root="fb24c8be-ff50-40f1-b561-f40929426da4"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Limited data on outcomes of pregnancies that have occurred following eculizumab use in pregnant women have not identified a concern for specific adverse developmental outcomes (see Data). There are risks to the mother and fetus associated with untreated paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) in pregnancy (<content styleCode="italics">see <linkHtml href="#s38">Clinical Considerations</linkHtml>
                                 </content>). Animal studies using a mouse analogue of the eculizumab molecule (murine anti-C5 antibody) showed increased rates of developmental abnormalities and an increased rate of dead and moribund offspring at doses 2-8 times the human dose (<content styleCode="italics">see <linkHtml href="#s40">Data</linkHtml>
                                 </content>).</paragraph>
                              <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defect and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20250402"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s38">
                           <id root="faf064ff-47ab-4a46-b949-39908b45cc74"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Considerations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250402"/>
                           <component>
                              <section ID="s39">
                                 <id root="4cc4ecf2-154a-4225-af43-be47f2358183"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Disease-Associated Maternal and/or Fetal/Neonatal Risk</content>
                                    </paragraph>
                                    <paragraph>PNH in pregnancy is associated with adverse maternal outcomes, including worsening cytopenias, thrombotic events, infections, bleeding, miscarriages and increased maternal mortality, and adverse fetal outcomes, including fetal death and premature delivery.</paragraph>
                                    <paragraph>aHUS in pregnancy is associated with adverse maternal outcomes, including pre-eclampsia and preterm delivery, and adverse fetal/neonatal outcomes, including intrauterine growth restriction (IUGR), fetal death and low birth weight.</paragraph>
                                 </text>
                                 <effectiveTime value="20250402"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="s40">
                           <id root="0e825c84-16a9-4b7d-9b88-75f965680388"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250402"/>
                           <component>
                              <section ID="s41">
                                 <id root="5e2d3b4d-4ea4-4757-8eeb-698f2767362e"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Human Data</content>
                                    </paragraph>
                                    <paragraph>A pooled analysis of prospectively (50.3%) and retrospectively (49.7%) collected data in more than 300 pregnant women with live births following exposure to eculizumab have not suggested safety concerns. However, these data cannot definitively exclude any drug-associated risk during pregnancy, because of the limited sample size.</paragraph>
                                 </text>
                                 <effectiveTime value="20250402"/>
                              </section>
                           </component>
                           <component>
                              <section ID="e41">
                                 <id root="6b160ada-9d26-435b-8a4d-b59044d04fee"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>Animal reproduction studies were conducted in mice using doses of a murine anti-C5 antibody that approximated 2-4 times (low dose) and 4-8 times (high dose) the recommended human eculizumab dose, based on a body weight comparison. When animal exposure to the antibody occurred in the time period from before mating until early gestation, no decrease in fertility or reproductive performance was observed. When maternal exposure to the antibody occurred during organogenesis, two cases of retinal dysplasia and one case of umbilical hernia were observed among 230 offspring born to mothers exposed to the higher antibody dose; however, the exposure did not increase fetal loss or neonatal death. When maternal exposure to the antibody occurred in the time period from implantation through weaning, a higher number of male offspring became moribund or died (1/25 controls, 2/25 low dose group, 5/25 high dose group). Surviving offspring had normal development and reproductive function.</paragraph>
                                 </text>
                                 <effectiveTime value="20250402"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s42">
                     <id root="b40cb319-5084-456c-9ad1-d6f2346e3731"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2  Lactation</title>
                     <effectiveTime value="20250402"/>
                     <component>
                        <section ID="s43">
                           <id root="765147a4-59fb-49a7-a83a-9808e916cc14"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Although limited published data does not report detectable levels of eculizumab in human milk, maternal IgG is known to be present in human milk. Available information is insufficient to inform the effect of eculizumab products on the breastfed infant. There are no data on the effects of eculizumab products on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for EPYSQLI and any potential adverse effects on the breastfed child from EPYSQLI or from the underlying maternal condition.</paragraph>
                           </text>
                           <effectiveTime value="20250402"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s44">
                     <id root="a93600d2-616b-4745-a01b-e767f0aa4773"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4  Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness of EPYSQLI for the treatment of PNH or gMG in pediatric patients have not been established.</paragraph>
                        <paragraph>The safety and effectiveness of EPYSQLI for the treatment of aHUS have been established in pediatric patients. Use of EPYSQLI in pediatric patients for this indication is supported by evidence from four adequate and well-controlled clinical studies assessing the safety and effectiveness of eculizumab for the treatment of aHUS. The studies included a total of 47 pediatric patients (ages 2 months to 17 years). The safety and effectiveness of eculizumab for the treatment of aHUS appear similar in pediatric and adult patients [<content styleCode="italics">see Adverse Reactions (<linkHtml href="#s27">6.1</linkHtml>), and Clinical Studies (<linkHtml href="#s64">14.2</linkHtml>)</content>].</paragraph>
                        <paragraph>Administer vaccinations for the prevention of infection due to Neisseria meningitidis, Streptococcus pneumoniae and Haemophilus influenzae type b (Hib) according to ACIP guidelines [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#s18">5.1</linkHtml>, <linkHtml href="#s20">5.3</linkHtml>)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20250402"/>
                  </section>
               </component>
               <component>
                  <section ID="s45">
                     <id root="50ff57c6-5175-4d72-a1a8-bfa0eb73cf3a"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5  Geriatric Use</title>
                     <text>
                        <paragraph>Fifty-one patients 65 years of age or older (15 with PNH, 4 with aHUS, 26 with gMG, and 6 with another indication) were treated with eculizumab in clinical trials in the approved indications. Although there were no apparent age-related differences observed in these studies, the number of patients aged 65 and over is not sufficient to determine whether they respond differently from younger patients.</paragraph>
                     </text>
                     <effectiveTime value="20250402"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s46">
               <id root="58a5aecb-c4d8-4308-9fc5-258264429ade"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11  DESCRIPTION</title>
               <text>
                  <paragraph>Eculizumab-aagh, a complement inhibitor, is a recombinant humanized monoclonal IgG2/4<sub>Ï°</sub> antibody produced in a Chinese Hamster Ovary cell line expression system and purified by standard bioprocess technology .</paragraph>
                  <paragraph>Eculizumab-aagh contains human constant regions from human IgG2 sequences and human IgG4 sequences and murine complementarity-determining regions grafted onto the human framework light- and heavy-chain variable regions. Eculizumab-aagh is composed of two 448 amino acid heavy chains and two 214 amino acid light chains and has a molecular weight of approximately 148 kDa.</paragraph>
                  <paragraph>EPYSQLI (eculizumab-aagh) injection is a sterile, preservative-free, clear to slightly opalescent and colorless solution for intravenous infusion and is supplied in a 30 mL single-dose vial. Each mL contains 10 mg of eculizumab-aagh, dibasic sodium phosphate (0.77 mg), monobasic sodium phosphate (0.55 mg), polysorbate 80 (0.22 mg) (vegetable origin), trehalose (86 mg), and Water for Injection, USP. The pH is 7.</paragraph>
               </text>
               <effectiveTime value="20250402"/>
            </section>
         </component>
         <component>
            <section ID="s47">
               <id root="94f42eb8-cd08-445e-8364-b5691d019db6"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12  CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250402"/>
               <component>
                  <section ID="s48">
                     <id root="9debd4d4-3d8d-4455-9359-60b2d3c64e14"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Eculizumab-aagh, the active ingredient in EPYSQLI, is a monoclonal antibody that specifically binds to the complement protein C5 with high affinity, thereby inhibiting its cleavage to C5a and C5b and preventing the generation of the terminal complement complex C5b-9.</paragraph>
                        <paragraph>Eculizumab products inhibit terminal complement-mediated intravascular hemolysis in PNH patients and complement-mediated thrombotic microangiopathy (TMA) in patients with aHUS.</paragraph>
                        <paragraph>The precise mechanism by which eculizumab exerts its therapeutic effect in gMG patients is unknown, but is presumed to involve reduction of terminal complement complex C5b-9 deposition at the neuromuscular junction.</paragraph>
                     </text>
                     <effectiveTime value="20250402"/>
                  </section>
               </component>
               <component>
                  <section ID="s49">
                     <id root="eec48946-8805-44b7-a2d0-9b51482dc960"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>In the placebo-controlled clinical study (PNH Study 1), eculizumab when administered as recommended reduced serum LDH levels from 2200 Â± 1034 U/L (mean Â± SD) at baseline to 700 Â± 388 U/L by week one and maintained the effect through the end of the study at week 26 (327 Â± 433 U/L) in patients with PNH. In the single arm clinical study (PNH Study 2), the effect was maintained through week 52 [<content styleCode="italics">see Clinical Studies (<linkHtml href="#s60">14</linkHtml>)</content>].</paragraph>
                        <paragraph>In patients with PNH, aHUS, and gMG, free C5 concentrations of &lt; 0.5 mcg/mL was correlated with complete blockade of terminal complement activity.</paragraph>
                     </text>
                     <effectiveTime value="20250402"/>
                  </section>
               </component>
               <component>
                  <section ID="s50">
                     <id root="f040f06c-6da4-4203-a54a-fe779c41aa70"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3  Pharmacokinetics</title>
                     <text>
                        <paragraph>Following intravenous maintenance doses of 900 mg once every 2 weeks in patients with PNH, the week 26 observed mean Â± SD serum eculizumab maximum concentration (C<sub>max</sub>) was 194 Â± 76 mcg/mL and the trough concentration (C<sub>trough</sub>) was 97 Â± 60 mcg/mL. Following intravenous maintenance doses of 1,200 mg once every 2 weeks in patients with aHUS, the week 26 observed mean Â± SD C<sub>trough</sub> was 242 Â± 101 mcg/mL. Following intravenous maintenance doses of 1,200 mg once every 2 weeks in patients with gMG, the week 26 observed mean Â± SD Cmax was 783 Â± 288 mcg/mL and the Ctrough was 341 Â± 172 mcg/mL.</paragraph>
                        <paragraph>Steady state was achieved 4 weeks after starting eculizumab treatment, with accumulation ratio of approximately 2-fold in all studied indications. Population pharmacokinetic analyses showed that eculizumab pharmacokinetics were dose-linear and time-independent over the 600 mg to 1,200 mg dose range, with inter-individual variability of 21% to 38%.</paragraph>
                     </text>
                     <effectiveTime value="20250402"/>
                     <component>
                        <section ID="s51">
                           <id root="263aa84d-efc5-4191-bee3-1372e01fced9"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Distribution</content>
                              </paragraph>
                              <paragraph>The eculizumab volume of distribution for a typical 70 kg patient was 5 L to 8 L.</paragraph>
                           </text>
                           <effectiveTime value="20250402"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s52">
                           <id root="5e089c65-4a92-422b-be9e-4938d8bb9bde"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elimination</content>
                              </paragraph>
                              <paragraph>The half-life of eculizumab was approximately 270 h to 414 h.</paragraph>
                              <paragraph>Plasma exchange or infusion increased the clearance of eculizumab by approximately 250-fold and reduced the half-life to 1.26 h. Supplemental dosing is recommended when EPYSQLI is administered to patients receiving plasma exchange or infusion [<content styleCode="italics">see Dosage and Administration (<linkHtml href="#s12">2.5</linkHtml>)</content>].</paragraph>
                           </text>
                           <effectiveTime value="20250402"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s53">
                           <id root="a6a53be1-b81c-46c3-9603-8a87373f190f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250402"/>
                           <component>
                              <section ID="s54">
                                 <id root="09eeb011-0c14-48fb-a16f-5f6d803e17f6"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Age, Sex, and Race:</content>
                                    </paragraph>
                                    <paragraph>The pharmacokinetics of eculizumab were not affected by age (2 months to 85 years), sex, or race.</paragraph>
                                 </text>
                                 <effectiveTime value="20250402"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s55">
                                 <id root="8787eda3-64ff-4dd8-9cbc-5c7aee4645c1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Renal Impairment:</content>
                                    </paragraph>
                                    <paragraph>Renal function did not affect the pharmacokinetics of eculizumab in PNH (creatinine clearance of 8 mL/min to 396 mL/min calculated using Cockcroft-Gault formula), aHUS (estimated glomerular filtration rate [eGFR] of 5 mL/min/1.73 m<sup>2</sup> to105 mL/min/1.73 m<sup>2</sup> using the Modification of Diet in Renal Disease [MDRD] formula), or gMG patients (eGFR of 44 mL/min/1.73 m<sup>2</sup> to 168 mL/min/1.73 m<sup>2</sup> using MDRD formula).</paragraph>
                                 </text>
                                 <effectiveTime value="20250402"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s57">
                     <id root="d0ee2f72-5c65-47f0-9d76-8bdd627b20af"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>12.6 Immunogenicity</title>
                     <text>
                        <paragraph>The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies, including those of eculizumab or of other eculizumab products.</paragraph>
                        <paragraph>The immunogenicity of eculizumab has been evaluated using two different immunoassays for the detection of anti-eculizumab antibodies: a direct enzyme-linked immunosorbent assay (ELISA) using the Fab fragment of eculizumab as target was used for the PNH indication; and an electro-chemiluminescence (ECL) bridging assay using the eculizumab whole molecule as target was used for the aHUS and gMG indications, as well as for additional patients with PNH. In the PNH population, antibodies to eculizumab were detected in 3/196 (2%) patients using the ELISA assay and in 5/161 (3%) patients using the ECL assay during the entire treatment period. In the aHUS population, antibodies to eculizumab were detected in 3/100 (3%) patients using the ECL assay during the entire treatment period. None of the 62 patients with gMG had antibodies to eculizumab detected following the 26-week active treatment.</paragraph>
                        <paragraph>An ECL based neutralizing assay with a low sensitivity of 2 mcg/mL was performed to detect neutralizing antibodies for the 5 patients with PNH and the 3 patients with aHUS with anti-eculizumab antibody positive samples using the ECL assay. Two of 161 patients with PNH (1.2%) and 1 of 100 patients with aHUS (1%) had low positive values for neutralizing antibodies.</paragraph>
                        <paragraph>No apparent correlation of antibody development to clinical response was observed.</paragraph>
                     </text>
                     <effectiveTime value="20250402"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s58">
               <id root="d7674e2b-be00-4f4d-9852-2f41b7cd26ac"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13  NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250402"/>
               <component>
                  <section ID="s59">
                     <id root="8d5fc1a7-c6b1-4ec4-95c3-2c5e5288d8ab"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Long-term animal carcinogenicity studies of eculizumab products have not been conducted.</paragraph>
                        <paragraph>Genotoxicity studies have not been conducted with eculizumab products.</paragraph>
                        <paragraph>Effects of eculizumab products upon fertility have not been studied in animals. Intravenous injections of male and female mice with a murine anti-C5 antibody at up to 4-8 times the equivalent of the clinical dose of eculizumab had no adverse effects on mating or fertility.</paragraph>
                     </text>
                     <effectiveTime value="20250402"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s60">
               <id root="47532079-42b8-4c42-bfcd-d50abb510edb"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14  CLINICAL STUDIES</title>
               <effectiveTime value="20250402"/>
               <component>
                  <section ID="s61">
                     <id root="e17aee04-2872-4846-8b3b-e2a3b4eaaa4f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1  Paroxysmal Nocturnal Hemoglobinuria (PNH)</title>
                     <text>
                        <paragraph>The safety and efficacy of eculizumab in PNH patients with hemolysis were assessed in a randomized, double-blind, placebo-controlled 26 week study (PNH Study 1, NCT00122330); PNH patients were also treated with eculizumab in a single arm 52 week study (PNH Study 2, NCT00122304) and in a long- term extension study (E05-001, NCT00122317). Patients received meningococcal vaccination prior to receipt of eculizumab. In all studies, the dose of eculizumab was 600 mg study drug every 7 Â± 2 days for 4 weeks, followed by 900 mg 7 Â± 2 days later, then 900 mg every 14 Â± 2 days for the study duration. Eculizumab was administered as an intravenous infusion over 25 - 45 minutes.</paragraph>
                     </text>
                     <effectiveTime value="20250402"/>
                     <component>
                        <section ID="s62">
                           <id root="ad60abe8-bb8a-46c4-9f8a-6260d35a5e87"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">PNH Study 1:</content>
                              </paragraph>
                              <paragraph>PNH patients with at least four transfusions in the prior 12 months, flow cytometric confirmation of at least 10% PNH cells and platelet counts of at least 100,000/microliter were randomized to either eculizumab (n = 43) or placebo (n = 44). Prior to randomization, all patients underwent an initial observation period to confirm the need for RBC transfusion and to identify the hemoglobin concentration (the "set-point") which would define each patient's hemoglobin stabilization and transfusion outcomes. The hemoglobin set-point was less than or equal to 9 g/dL in patients with symptoms and was less than or equal to 7 g/dL in patients without symptoms. Endpoints related to hemolysis included the numbers of patients achieving hemoglobin stabilization, the number of RBC units transfused, fatigue, and health-related quality of life. To achieve a designation of hemoglobin stabilization, a patient had to maintain a hemoglobin concentration above the hemoglobin set-point and avoid any RBC transfusion for the entire 26 week period. Hemolysis was monitored mainly by the measurement of serum LDH levels, and the proportion of PNH RBCs was monitored by flow cytometry. Patients receiving anticoagulants and systemic corticosteroids at baseline continued these medications. Major baseline characteristics were balanced (see <linkHtml href="#t9">Table 9</linkHtml>).</paragraph>
                              <table ID="t9" width="100%" styleCode="Noautorules">
                                 <caption>Table 9: PNH Study 1 Patient Baseline Characteristics</caption>
                                 <col width="54.515%" align="left"/>
                                 <col width="22.359%" align="left"/>
                                 <col width="23.126%" align="left"/>
                                 <tbody>
                                    <tr>
                                       <td align="center" valign="middle"/>
                                       <td colspan="2" align="center" valign="middle">
                                          <content styleCode="bold">Study 1</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="center" valign="middle" styleCode="Botrule">
                                          <content styleCode="bold">Parameter</content>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Botrule">
                                          <content styleCode="bold">Placebo</content>
                                          <br/>
                                          <content styleCode="bold">(N=44)</content>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Botrule">
                                          <content styleCode="bold">Eculizumab</content>
                                          <br/>
                                          <content styleCode="bold">(N=43)</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">Mean age (SD)</td>
                                       <td align="center" valign="middle">38 (13)</td>
                                       <td align="center" valign="middle">42 (16)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">Gender - female (%)</td>
                                       <td align="center" valign="middle">29 (66)</td>
                                       <td align="center" valign="middle">23 (54)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">History of aplastic anemia or myelodysplastic syndrome (%)</td>
                                       <td align="center" valign="middle">12 (27)</td>
                                       <td align="center" valign="middle">8 (19)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">Patients with history of thrombosis (events)</td>
                                       <td align="center" valign="middle">8 (11)</td>
                                       <td align="center" valign="middle">9 (16)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">Concomitant anticoagulants (%)</td>
                                       <td align="center" valign="middle">20 (46)</td>
                                       <td align="center" valign="middle">24 (56)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">Concomitant steroids/immunosuppressant treatments (%)</td>
                                       <td align="center" valign="middle">16 (36)</td>
                                       <td align="center" valign="middle">14 (33)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">Packed RBC units transfused per patient in previous 12 months (median (Q1,Q3))</td>
                                       <td align="center" valign="middle">17 (14, 25)</td>
                                       <td align="center" valign="middle">18 (12, 24)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">Mean Hgb level (g/dL) at setpoint (SD)</td>
                                       <td align="center" valign="top">8 (1)</td>
                                       <td align="center" valign="top">8 (1)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">Pre-treatment LDH levels (median, U/L)</td>
                                       <td align="center" valign="top">2,234</td>
                                       <td align="center" valign="top">2,032</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top">Free hemoglobin at baseline (median, mg/dL)</td>
                                       <td align="center" valign="top">46</td>
                                       <td align="center" valign="top">41</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>Patients treated with eculizumab had significantly reduced (p&lt; 0.001) hemolysis resulting in improvements in anemia as indicated by increased hemoglobin stabilization and reduced need for RBC transfusions compared to placebo treated patients (see <linkHtml href="#t10">Table 10</linkHtml>). These effects were seen among patients within each of the three pre-study RBC transfusion strata (4 - 14 units; 15 - 25 units; &gt; 25 units). After 3 weeks of eculizumab treatment, patients reported less fatigue and improved health- related quality of life. Because of the study sample size and duration, the effects of eculizumab products on thrombotic events could not be determined.</paragraph>
                              <table ID="t10" width="100%" styleCode="Noautorules">
                                 <caption>Table 10: PNH Study 1 Results</caption>
                                 <col width="54.515%" align="left"/>
                                 <col width="22.359%" align="left"/>
                                 <col width="23.126%" align="left"/>
                                 <thead>
                                    <tr>
                                       <th align="left" valign="middle" styleCode="Botrule"/>
                                       <th align="center" valign="middle" styleCode="Botrule">
                                          <content styleCode="bold">Placebo</content>
                                          <br/>
                                          <content styleCode="bold">(N=44)</content>
                                       </th>
                                       <th align="center" valign="middle" styleCode="Botrule">
                                          <content styleCode="bold">Eculizumab</content>
                                          <br/>
                                          <content styleCode="bold">(N=43)</content>
                                       </th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr>
                                       <td align="left" valign="middle">Percentage of patients with stabilized hemoglobin levels</td>
                                       <td align="center" valign="middle">0</td>
                                       <td align="center" valign="middle">49</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">Packed RBC units transfused per patient (median)</td>
                                       <td align="center" valign="middle">10</td>
                                       <td align="center" valign="middle">0</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">(range)</td>
                                       <td align="center" valign="middle">(2 - 21)</td>
                                       <td align="center" valign="middle">(0 - 16)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">Transfusion avoidance (%)</td>
                                       <td align="center" valign="middle">0</td>
                                       <td align="center" valign="middle">51</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">LDH levels at end of study (median, U/L)</td>
                                       <td align="center" valign="middle">2,167</td>
                                       <td align="center" valign="middle">239</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle">Free hemoglobin at end of study (median, mg/dL)</td>
                                       <td align="center" valign="middle">62</td>
                                       <td align="center" valign="middle">5</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20250402"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s63">
                           <id root="a5c4fdd3-a51b-43a8-a155-3427ec7121a7"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">PNH Study 2 and Extension Study:</content>
                              </paragraph>
                              <paragraph>PNH patients with at least one transfusion in the prior 24 months and at least 30,000 platelets/microliter received eculizumab over a 52-week period. Concomitant medications included anti- thrombotic agents in 63% of the patients and systemic corticosteroids in 40% of the patients. Overall, 96 of the 97 enrolled patients completed the study (one patient died following a thrombotic event). A reduction in intravascular hemolysis as measured by serum LDH levels was sustained for the treatment period and resulted in a reduced need for RBC transfusion and less fatigue. 187 eculizumab- treated PNH patients were enrolled in a long term extension study. All patients sustained a reduction in intravascular hemolysis over a total eculizumab exposure time ranging from 10 to 54 months. There were fewer thrombotic events with eculizumab treatment than during the same period of time prior to treatment. However, the majority of patients received concomitant anticoagulants; the effects of anticoagulant withdrawal during eculizumab products therapy was not studied [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#s24">5.5</linkHtml>)</content>].</paragraph>
                           </text>
                           <effectiveTime value="20250402"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s64">
                     <id root="1710a3cd-68fd-4466-bbaa-bd5d781db50a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2  Atypical Hemolytic Uremic Syndrome (aHUS)</title>
                     <text>
                        <paragraph>Five single-arm studies [four prospective: C08-002A/B (NCT00844545 and NCT00844844), C08- 003A/B (NCT00838513 and NCT00844428), C10-003 (NCT01193348), and C10-004 (NCT01194973); and one retrospective: C09-001r (NCT01770951)] evaluated the safety and efficacy of eculizumab for the treatment of aHUS. Patients with aHUS received meningococcal vaccination prior to receipt of eculizumab or received prophylactic treatment with antibiotics until 2 weeks after vaccination. In all studies, the dose of eculizumab in adult and adolescent patients was 900 mg every 7 Â± 2 days for 4 weeks, followed by 1,200 mg 7 Â± 2 days later, then 1,200 mg every 14 Â± 2 days thereafter. The dosage regimen for pediatric patients weighing less than 40 kg enrolled in Study C09-001r and Study C10-003 was based on body weight [<content styleCode="italics">see Dosage and Administration (<linkHtml href="#s10">2.3</linkHtml>)</content>]. Efficacy evaluations were based on thrombotic microangiopathy (TMA) endpoints.</paragraph>
                        <paragraph>Endpoints related to TMA included the following:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>platelet count change from baseline</item>
                           <item>hematologic normalization (<content styleCode="italics">maintenance of normal platelet counts and LDH levels for at least four weeks)</content>
                           </item>
                           <item>complete TMA response (<content styleCode="italics">hematologic normalization plus at least a 25% reduction in serum creatinine for a minimum of four weeks</content>)</item>
                           <item>TMA-event free status (<content styleCode="italics">absence for at least 12 weeks of a decrease in platelet count of &gt;25% from baseline, plasma exchange or plasma infusion, and new dialysis requirement)</content>
                           </item>
                           <item>Daily TMA intervention rate (<content styleCode="italics">defined as the number of plasma exchange or plasma infusion interventions and the number of new dialyses required per patient per day</content>).</item>
                        </list>
                     </text>
                     <effectiveTime value="20250402"/>
                     <component>
                        <section ID="s65">
                           <id root="041963c7-16a5-482a-8f63-a00e0478f699"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">aHUS Resistant to PE/PI (Study C08-002A/B)</content>
                              </paragraph>
                              <paragraph>Study C08-002A/B enrolled patients who displayed signs of thrombotic microangiopathy (TMA) despite receiving at least four PE/PI treatments the week prior to screening. One patient had no PE/PI the week prior to screening because of PE/PI intolerance. In order to qualify for enrollment, patients were required to have a platelet count â¤150 x 10<sup>9</sup>/L, evidence of hemolysis such as an elevation in serum LDH, and serum creatinine above the upper limits of normal, without the need for chronic dialysis. The median patient age was 28 (range: 17 to 68 years). Patients enrolled in Study C08- 002A/B were required to have ADAMTS13 activity level above 5%; observed range of values in the trial were 70%-121%. Seventy-six percent of patients had an identified complement regulatory factor mutation or auto-antibody. <linkHtml href="#t11">Table 11</linkHtml> summarizes the key baseline clinical and disease-related characteristics of patients enrolled in Study C08-002A/B.</paragraph>
                              <table ID="t11" width="100%">
                                 <caption>Table 11: Baseline Characteristics of Patients Enrolled in Study C08-002A/B</caption>
                                 <col width="65.950%" align="left"/>
                                 <col width="34.050%" align="left"/>
                                 <tbody>
                                    <tr>
                                       <td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule">
                                          <content styleCode="bold">Parameter</content>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">C08-002A/B</content>
                                          <br/>
                                          <content styleCode="bold">(N=17)</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">Time from aHUS diagnosis until screening in months, median (min, max)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">10 (0.26, 236)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">Time from current clinical TMA manifestation until screening in months, median (min, max)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">&lt;1 (&lt;1, 4)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">Baseline platelet count (Ã 10<sup>9</sup>/L), median (range)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">118 (62, 161)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">Baseline LDH (U/L), median (range)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">269 (134, 634)</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>Patients in Study C08-002A/B received eculizumab for a minimum of 26 weeks. In Study C08-002A/B, the median duration of eculizumab therapy was approximately 100 weeks (range: 2 weeks to 145 weeks).</paragraph>
                              <paragraph>Renal function, as measured by eGFR, was improved and maintained during eculizumab therapy. The mean eGFR (Â± SD) increased from 23 Â± 15 mL/min/1.73m<sup>2</sup> at baseline to 56 Â± 40 mL/min/1.73m<sup>2</sup> by 26 weeks; this effect was maintained through 2 years (56 Â± 30 mL/min/1.73m<sup>2</sup>). Four of the five patients who required dialysis at baseline were able to discontinue dialysis.</paragraph>
                              <paragraph>Reduction in terminal complement activity and an increase in platelet count relative to baseline were observed after commencement of eculizumab. Eculizumab reduced signs of complement-mediated TMA activity, as shown by an increase in mean platelet counts from baseline to 26 weeks. In Study C08- 002A/B, mean platelet count (Â± SD) increased from 109 Â± 32 x10<sup>9</sup>/L at baseline to 169 Â± 72 x10<sup>9</sup>/L by one week; this effect was maintained through 26 weeks (210 Â± 68 x10<sup>9</sup>/L), and 2 years (205 Â± 46 x10<sup>9</sup>/L). When treatment was continued for more than 26 weeks, two additional patients achieved Hematologic Normalization as well as Complete TMA response. Hematologic Normalization and Complete TMA response were maintained by all responders. In Study C08-002A/B, responses to eculizumab were similar in patients with and without identified mutations in genes encoding complement regulatory factor proteins.</paragraph>
                              <paragraph>
                                 <linkHtml href="#t12">Table 12</linkHtml> summarizes the efficacy results for Study C08-002A/B.</paragraph>
                              <table ID="t12" width="100%">
                                 <caption>Table 12: Efficacy Results for Study C08-002A/B</caption>
                                 <col width="57.067%" align="left"/>
                                 <col width="23.967%" align="left"/>
                                 <col width="18.967%" align="left"/>
                                 <tfoot>
                                    <tr>
                                       <td colspan="3" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>1.</sup>At data cut-off (September 8, 2010).</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="3" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>2.</sup>At data cut-off (April 20, 2012).</paragraph>
                                       </td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule">
                                          <content styleCode="bold">Efficacy Parameter</content>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Study C08-002A/B at 26 wks</content>
                                          <content styleCode="bold">
                                             <sup>1</sup>
                                          </content>
                                          <br/>
                                          <content styleCode="bold">(N=17)</content>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Study C08-002A/B at 2 yrs</content>
                                          <content styleCode="bold">
                                             <sup>2</sup>
                                          </content>
                                          <br/>
                                          <content styleCode="bold">(N=17)</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">Complete TMA response, n (%)<br/>Median Duration of complete TMA response, weeks (range)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">11 (65)<br/>38 (25, 56)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">13 (77)<br/>99 (25, 139)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">eGFR improvement â¥15 mL/min/1.73 m<sup>2</sup>, n (%)<br/>Median duration of eGFR improvement, days (range)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">9 (53)<br/>251 (70, 392)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">10 (59)<br/>ND</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">Hematologic normalization, n (%)<br/>Median Duration of hematologic normalization, weeks (range)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">13 (76)<br/>37 (25, 62)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">15 (88)<br/>99 (25, 145)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">TMA event-free status, n (%)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">15 (88)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">15 (88)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">Daily TMA intervention rate, median (range)<br/>Â  Â  Â Before eculizumab<br/>Â  Â  Â On eculizumab treatment</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">
                                          <br/>0.82 (0.04, 1.52)<br/>0 (0, 0.31)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">
                                          <br/>0.82 (0.04, 1.52)<br/>0 (0, 0.36)</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20250402"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s66">
                           <id root="9560a523-7238-40ee-b4fd-3caa1020da97"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">aHUS Sensitive to PE/PI (Study C08-003A/B)</content>
                              </paragraph>
                              <paragraph>Study C08-003A/B enrolled patients undergoing chronic PE/PI who generally did not display hematologic signs of ongoing thrombotic microangiopathy (TMA). All patients had received PT at least once every two weeks, but no more than three times per week, for a minimum of eight weeks prior to the first eculizumab dose. Patients on chronic dialysis were permitted to enroll in Study C08- 003A/B. The median patient age was 28 years (range: 13 to 63 years). Patients enrolled in Study C08- 003A/B were required to have ADAMTS13 activity level above 5%; observed range of values in the trial were 37%-118%. Seventy percent of patients had an identified complement regulatory factor mutation or auto-antibody. <linkHtml href="#t13">Table 13</linkHtml> summarizes the key baseline clinical and disease-related characteristics of patients enrolled in Study C08-003A/B.</paragraph>
                              <table ID="t13" width="100%">
                                 <caption>Table 13: Baseline Characteristics of Patients Enrolled in Study C08-003A/B</caption>
                                 <col width="64.900%" align="left"/>
                                 <col width="35.100%" align="left"/>
                                 <tbody>
                                    <tr>
                                       <td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule">
                                          <content styleCode="bold">Parameter</content>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Study C08-003A/B</content>
                                          <br/>
                                          <content styleCode="bold">(N=20)</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">Time from aHUS diagnosis until screening in months, median (min, max)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">48 (0.66, 286)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">Time from current clinical TMA manifestation until screening in months, median (min, max)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">9 (1, 45)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">Baseline platelet count (Ã 10<sup>9</sup>/L), median (range)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">218 (105, 421)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">Baseline LDH (U/L), median (range)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">200 (151, 391)</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>Patients in Study C08-003A/B received eculizumab for a minimum of 26 weeks. In Study C08-003A/B, the median duration of eculizumab therapy was approximately 114 weeks (range: 26 to 129 weeks).</paragraph>
                              <paragraph>Renal function, as measured by eGFR, was maintained during eculizumab therapy. The mean eGFR (Â± SD) was 31 Â± 19 mL/min/1.73m<sup>2</sup> at baseline, and was maintained through 26 weeks (37 Â± 21 mL/min/1.73m<sup>2</sup>) and 2 years (40 Â± 18 mL/min/1.73m<sup>2</sup>). No patient required new dialysis with eculizumab.</paragraph>
                              <paragraph>Reduction in terminal complement activity was observed in all patients after the commencement of eculizumab. Eculizumab reduced signs of complement-mediated TMA activity, as shown by an increase in mean platelet counts from baseline to 26 weeks. Platelet counts were maintained at normal levels despite the elimination of PE/PI. The mean platelet count (Â± SD) was 228 Â± 78 x 10<sup>9</sup>/L at baseline, 233 Â± 69 x 10<sup>9</sup>/L at week 26, and 224 Â± 52 x 10<sup>9</sup>/L at 2 years. When treatment was continued for more than 26 weeks, six additional patients achieved Complete TMA response. Complete TMA Response and Hematologic Normalization were maintained by all responders. In Study C08-003A/B, responses to eculizumab were similar in patients with and without identified mutations in genes encoding complement regulatory factor proteins.</paragraph>
                              <paragraph>
                                 <linkHtml href="#t14">Table 14</linkHtml> summarizes the efficacy results for Study C08-003A/B.</paragraph>
                              <table ID="t14" width="100%" styleCode="Noautorules">
                                 <caption>Table 14: Efficacy Results for Study C08-003A/B</caption>
                                 <col width="46.933%" align="left"/>
                                 <col width="27.600%" align="left"/>
                                 <col width="25.467%" align="left"/>
                                 <tfoot>
                                    <tr>
                                       <td colspan="3" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>1.</sup> At data cut-off (September 8, 2010).</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="3" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>2.</sup> At data cut-off (April 20, 2012).</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="3" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>3.</sup> Calculated at each post-dose day of measurement (excluding Days 1 to 4) using a repeated measurement ANOVA model.</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="3" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>4.</sup> In Study C08-003A/B, 85% of patients had normal platelet counts and 80% of patients had normal serum LDH levels at baseline, so hematologic normalization in this population reflects maintenance of normal parameters in the absence of PE/PI.</paragraph>
                                       </td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule">
                                          <content styleCode="bold">Efficacy Parameter</content>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Study C08-003A/B</content>
                                          <br/>
                                          <content styleCode="bold">at 26 wks</content>
                                          <content styleCode="bold">
                                             <sup>1</sup>
                                          </content>
                                          <br/>
                                          <content styleCode="bold">(N=20)</content>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Study C08-003A/B</content>
                                          <br/>
                                          <content styleCode="bold">at 2 yrs</content>
                                          <content styleCode="bold">
                                             <sup>2</sup>
                                          </content>
                                          <br/>
                                          <content styleCode="bold">(N=20)</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">Complete TMA response, n (%)<br/>Median duration of complete TMA response, weeks (range)</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">5 (25)<br/>32 (12, 38)</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">11 (55)<br/>68 (38, 109)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">Â  Â  Â eGFR improvement â¥15 mL/min/1.73 m<sup>2</sup>, n (%)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">1 (5)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">8 (40)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">TMA Event-free status n (%)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">16 (80)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">19 (95)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">Daily TMA intervention rate, median (range)<br/>Â  Â  Â Before eculizumab<br/>Â  Â  Â On eculizumab treatment</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">
                                          <br/>0.23 (0.05, 1.07)<br/>0</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">
                                          <br/>0.23 (0.05, 1.07)<br/>0 (0, 0.01)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">Hematologic normalization<sup>4</sup>, n (%)<br/>Median duration of hematologic normalization, weeks (range)<sup>3</sup>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">
                                          <br/>18 (90)<br/>38 (22, 52)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">
                                          <br/>18 (90)<br/>114 (33, 125)</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20250402"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s67">
                           <id root="7ff650bd-0869-4271-9d4d-048ba008c63d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Retrospective Study in Patients with aHUS (C09-001r)</content>
                              </paragraph>
                              <paragraph>The efficacy results for the aHUS retrospective study (Study C09-001r) were generally consistent with results of the two prospective studies. Eculizumab reduced signs of complement-mediated TMA activity, as shown by an increase in mean platelet counts from baseline. Mean platelet count (Â± SD) increased from 171 Â± 83 x10<sup>9</sup>/L at baseline to 233 Â±109 x10<sup>9</sup>/L after one week of therapy; this effect was maintained through 26 weeks (mean platelet count (Â± SD) at week 26: 254 Â± 79 x10<sup>9</sup>/L).</paragraph>
                              <paragraph>A total of 19 pediatric patients (ages 2 months to 17 years) received eculizumab in Study C09-001r. The median duration of eculizumab therapy was 16 weeks (range 4 to 70 weeks) for children &lt;2 years of age (n=5), 31 weeks (range 19 to 63 weeks) for children 2 to &lt;12 years of age (n=10), and 38 weeks (range 1 to 69 weeks) for patients 12 to &lt;18 years of age (n=4). Fifty-three percent of pediatric patients had an identified complement regulatory factor mutation or auto-antibody.</paragraph>
                              <paragraph>Overall, the efficacy results for these pediatric patients appeared consistent with what was observed in patients enrolled in Studies C08-002A/B and C08-003A/B (<linkHtml href="#t15">Table 15</linkHtml>). No pediatric patient required new dialysis during treatment with eculizumab.</paragraph>
                              <table ID="t15" width="100%">
                                 <caption>Table 15: Efficacy Results in Pediatric Patients Enrolled in Study C09-001r</caption>
                                 <col width="36.440%" align="left"/>
                                 <col width="13.580%" align="left"/>
                                 <col width="16.260%" align="left"/>
                                 <col width="14.880%" align="left"/>
                                 <col width="18.840%" align="left"/>
                                 <tfoot>
                                    <tr>
                                       <td colspan="5" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>1.</sup> Platelet count normalization was defined as a platelet count of at least 150,000 X 10<sup>9</sup>/L on at least two consecutive measurements spanning a period of at least 4 weeks.</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="5" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>2.</sup> Of the 9 patients who experienced an eGFR improvement of at least 15 mL/min/1.73 m<sup>2</sup>, one received dialysis throughout the study period and another received eculizumab as prophylaxis following renal allograft transplantation.</paragraph>
                                       </td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule">
                                          <content styleCode="bold">Efficacy Parameter</content>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">&lt;2 yrs</content>
                                          <br/>
                                          <content styleCode="bold">(N=5)</content>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">2 to &lt;12 yrs</content>
                                          <br/>
                                          <content styleCode="bold">(N=10)</content>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">12 to &lt;18 yrs</content>
                                          <br/>
                                          <content styleCode="bold">(N=4)</content>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Total</content>
                                          <br/>
                                          <content styleCode="bold">(N=19)</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">Complete TMA response, n (%)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">2 (40)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">5 (50)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">1 (25)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">8 (42)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">Patients with eGFR improvement â¥ 15 mL/min/1.73 m<sup>2</sup>, n (%)<sup>2</sup>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">2 (40)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">6 (60)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">1 (25)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">9 (47)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">Â  Â  Â Platelet count normalization, n (%)<sup>1</sup>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">4 (80)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">10 (100)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">3 (75)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">17 (89)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">Hematologic Normalization, n (%)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">2 (40)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">5 (50)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">1 (25)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">8 (42)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">Daily TMA intervention rate, median (range)<br/>Â  Â  Â Before eculizumab<br/>Â  Â  Â On eculizumab treatment</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">
                                          <br/>
                                          <br/>1 (0, 2)<br/>&lt;1 (0, &lt;1)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">
                                          <br/>
                                          <br/>&lt;1 (0.07, 1.46)<br/>0 (0, &lt;1)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">
                                          <br/>
                                          <br/>&lt;1 (0, 1)<br/>0 (0, &lt;1)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">
                                          <br/>
                                          <br/>0.31 (0.00, 2.38)<br/>0.00 (0.00 , 0.08)</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20250402"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s68">
                           <id root="441dc9a6-7f7c-4a87-ae67-419768aedb0c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Adult Patients with aHUS (Study C10-004)</content>
                              </paragraph>
                              <paragraph>Study C10-004 enrolled patients who displayed signs of thrombotic microangiopathy (TMA). In order to qualify for enrollment, patients were required to have a platelet count &lt; lower limit of normal range (LLN), evidence of hemolysis such as an elevation in serum LDH, and serum creatinine above the upper limits of normal, without the need for chronic dialysis. The median patient age was 35 (range: 18 to 80 years). All patients enrolled in Study C10-004 were required to have ADAMTS13 activity level above 5%; observed range of values in the trial were 28%-116%. Fifty-one percent of patients had an identified complement regulatory factor mutation or auto-antibody. A total of 35 patients received PE/PI prior to eculizumab. <linkHtml href="#t16">Table 16</linkHtml> summarizes the key baseline clinical and disease-related characteristics of patients enrolled in Study C10-004.</paragraph>
                              <table ID="t16" width="100%">
                                 <caption>Table 16: Baseline Characteristics of Patients Enrolled in Study C10-004</caption>
                                 <col width="66.100%" align="left"/>
                                 <col width="33.900%" align="left"/>
                                 <tbody>
                                    <tr>
                                       <td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule">
                                          <content styleCode="bold">Parameter</content>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Study C10-004</content>
                                          <br/>
                                          <content styleCode="bold">(N=41)</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">Time from aHUS diagnosis until start of study drug in months, median (range)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">0.79 (0.03 â 311)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">Time from current clinical TMA manifestation until first study dose in months, median (range)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">0.52 (0.03-19)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">Baseline platelet count (Ã 10<sup>9</sup>/L), median (range)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">125 (16 â 332)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">Baseline LDH (U/L), median (range)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">375 (131 â 3318)</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>Patients in Study C10-004 received eculizumab for a minimum of 26 weeks. In Study C10-004, the median duration of eculizumab therapy was approximately 50 weeks (range: 13 weeks to 86 weeks).</paragraph>
                              <paragraph>Renal function, as measured by eGFR, was improved during eculizumab therapy. The mean eGFR (Â± SD) increased from 17 Â± 12 mL/min/1.73m<sup>2</sup> at baseline to 47 Â± 24 mL/min/1.73m<sup>2</sup> by 26 weeks. Twenty of the 24 patients who required dialysis at study baseline were able to discontinue dialysis during eculizumab treatment.</paragraph>
                              <paragraph>Reduction in terminal complement activity and an increase in platelet count relative to baseline were observed after commencement of eculizumab. Eculizumab reduced signs of complement-mediated TMA activity, as shown by an increase in mean platelet counts from baseline to 26 weeks. In Study C10- 004, mean platelet count (Â± SD) increased from 119 Â± 66 x10<sup>9</sup>/L at baseline to 200 Â± 84 x10<sup>9</sup>/L by one week; this effect was maintained through 26 weeks (mean platelet count (Â± SD) at week 26: 252 Â± 70 x10<sup>9</sup>/L). In Study C10-004, responses to eculizumab were similar in patients with and without identified mutations in genes encoding complement regulatory factor proteins or auto-antibodies to factor H.</paragraph>
                              <paragraph>
                                 <linkHtml href="#t17">Table 17</linkHtml> summarizes the efficacy results for Study C10-004.</paragraph>
                              <table ID="t17" width="100%">
                                 <caption>Table 17: Efficacy Results for Study C10-004</caption>
                                 <col width="71.450%" align="left"/>
                                 <col width="28.550%" align="left"/>
                                 <tbody>
                                    <tr>
                                       <td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule">
                                          <content styleCode="bold">Efficacy Parameter</content>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Study C10-004</content>
                                          <br/>
                                          <content styleCode="bold">(N=41)</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">Complete TMA response, n (%),<br/>Â  Â  Â 95% CI<br/>Median duration of complete TMA response, weeks (range)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">23 (56)<br/>40,72<br/>42 (6, 75)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">Patients with eGFR improvement â¥ 15 mL/min/1.73m<sup>2</sup>, n (%)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">22 (54)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">Hematologic Normalization, n (%)<br/>Median duration of hematologic normalization, weeks (range)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">36 (88)<br/>46 (10, 75)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">TMA Event-free Status, n (%)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">37 (90)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">Daily TMA Intervention Rate, median (range)<br/>Â  Â  Â Before eculizumab<br/>Â  Â  Â On eculizumab treatment</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">
                                          <br/>0.63 (0, 1.38)<br/>0 (0, 0.58)</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20250402"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s69">
                           <id root="3e20e169-e917-46da-a4c4-39c045cf4d91"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Pediatric and Adolescent Patients with aHUS (Study C10-003)</content>
                              </paragraph>
                              <paragraph>Study C10-003 enrolled patients who were required to have a platelet count &lt; lower limit of normal range (LLN), evidence of hemolysis such as an elevation in serum LDH above the upper limits of normal, serum creatinine level â¥97 percentile for age without the need for chronic dialysis. The median patient age was 6.5 (range: 5 months to 17 years). Patients enrolled in Study C10-003 were required to have ADAMTS13 activity level above 5%; observed range of values in the trial were 38%-121%. Fifty percent of patients had an identified complement regulatory factor mutation or auto-antibody. A total of 10 patients received PE/PI prior to eculizumab. <linkHtml href="#t18">Table 18</linkHtml> summarizes the key baseline clinical and disease-related characteristics of patients enrolled in Study C10-003.</paragraph>
                              <table ID="t18" width="100%">
                                 <caption>Table 18: Baseline Characteristics of Patients Enrolled in Study C10-003</caption>
                                 <col width="51.067%" align="left"/>
                                 <col width="27.467%" align="left"/>
                                 <col width="21.467%" align="left"/>
                                 <tbody>
                                    <tr>
                                       <td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule">
                                          <content styleCode="bold">Parameter</content>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Patients</content>
                                          <br/>
                                          <content styleCode="bold">1 month to &lt;12 years</content>
                                          <br/>
                                          <content styleCode="bold">(N=18)</content>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">All Patients</content>
                                          <br/>
                                          <content styleCode="bold">(N=22)</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">Time from aHUS diagnosis until start of study drug in months, median (range)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">0.51 (0.03 â 58)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">0.56 (0.03-191)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">Time from current clinical TMA manifestation until first study dose in months, median (range)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">0.23 (0.03 â 4)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">0.2 (0.03-4)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">Baseline platelet count (x 10<sup>9</sup>/L), median (range)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">110 (19-146)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">91 (19-146)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">Baseline LDH (U/L) median (range)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">1510 (282-7164)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">1244 (282-7164)</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>Patients in Study C10-003 received eculizumab for a minimum of 26 weeks. In Study C10-003, the median duration of eculizumab therapy was approximately 44 weeks (range: 1 dose to 88 weeks).</paragraph>
                              <paragraph>Renal function, as measured by eGFR, was improved during eculizumab therapy. The mean eGFR (Â± SD) increased from 33 Â± 30 mL/min/1.73m<sup>2</sup> at baseline to 98 Â± 44 mL/min/1.73m<sup>2</sup> by 26 weeks. Among the 20 patients with a CKD stage â¥2 at baseline, 17 (85%) achieved a CKD improvement of â¥1 stage. Among the 16 patients ages 1 month to &lt;12 years with a CKD stage â¥2 at baseline, 14 (88%) achieved a CKD improvement by â¥1 stage. Nine of the 11 patients who required dialysis at study baseline were able to discontinue dialysis during eculizumab treatment. Responses were observed across all ages from 5 months to 17 years of age.</paragraph>
                              <paragraph>Reduction in terminal complement activity was observed in all patients after commencement of eculizumab. Eculizumab reduced signs of complement-mediated TMA activity, as shown by an increase in mean platelet counts from baseline to 26 weeks. The mean platelet count (Â± SD) increased from 88 Â± 42 x10<sup>9</sup>/L at baseline to 281 Â± 123 x10<sup>9</sup>/L by one week; this effect was maintained through 26 weeks (mean platelet count (Â±SD) at week 26: 293 Â± 106 x10<sup>9</sup>/L). In Study C10-003, responses to eculizumab were similar in patients with and without identified mutations in genes encoding complement regulatory factor proteins or auto-antibodies to factor H.</paragraph>
                              <paragraph>
                                 <linkHtml href="#t19">Table 19</linkHtml> summarizes the efficacy results for Study C10-003.</paragraph>
                              <table ID="t19" width="100%">
                                 <caption>Table 19: Efficacy Results for Study C10-003</caption>
                                 <col width="52.500%" align="left"/>
                                 <col width="25.333%" align="left"/>
                                 <col width="22.167%" align="left"/>
                                 <tfoot>
                                    <tr>
                                       <td colspan="3" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>1.</sup> Through data cutoff (October 12, 2012).</paragraph>
                                       </td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule">
                                          <content styleCode="bold">Efficacy Parameter</content>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Patients</content>
                                          <br/>
                                          <content styleCode="bold">1 month to &lt;12 years (N=18)</content>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">All Patients</content>
                                          <br/>
                                          <content styleCode="bold">(N=22)</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">Complete TMA response, n (%)<br/>Â  Â  Â 95% CI<br/>Median Duration of complete TMA response, weeks (range)<sup>1</sup>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">11 (61)<br/>36, 83<br/>40 (14, 77)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">14 (64)<br/>41, 83<br/>37 (14, 77)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">eGFR improvement â¥15 mL/min/ 1.73 m<sup>2</sup>â¢n (%)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">16 (89)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">19 (86)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">Complete Hematologic Normalization, n (%)<br/>Median Duration of complete hematologic normalization, weeks (range)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">14 (78)<br/>38 (14, 77)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">18 (82)<br/>38 (14, 77)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">TMA Event-Free Status, n (%)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">17 (94)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">21 (95)</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">Daily TMA Intervention rate, median (range)<br/>Â  Â  Â Before eculizumab treatment<br/>Â  Â  Â On eculizumab treatment</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">0.2 (0, 1.7)<br/>0 (0, 0.01)</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">0.4 (0, 1.7)<br/>0 (0, 0.01)</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20250402"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s70">
                     <id root="78ab48d6-5806-4c2d-8f2d-cdf4b72ac689"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.3 Generalized Myasthenia Gravis (gMG)</title>
                     <text>
                        <paragraph>The efficacy of eculizumab for the treatment of gMG was established in gMG Study 1 (NCT01997229), a 26-week randomized, double-blind, parallel-group, placebo-controlled, multi-center trial that enrolled patients who met the following criteria at screening:</paragraph>
                        <list listType="ordered" styleCode="Arabic">
                           <item>Positive serologic test for anti-AChR antibodies,</item>
                           <item>Myasthenia Gravis Foundation of America (MGFA) Clinical Classification Class II to IV,</item>
                           <item>MG-Activities of Daily Living (MG-ADL) total score â¥6,</item>
                           <item>Failed treatment over 1 year or more with 2 or more immunosuppressive therapies (ISTs) either in combination or as monotherapy, or failed at least 1 IST and required chronic plasmapheresis or plasma exchange (PE) or intravenous immunoglobulin (IVIg).</item>
                        </list>
                        <paragraph>A total of 62 patients were randomized to receive eculizumab treatment and 63 were randomized to receive placebo. Baseline characteristics were similar between treatment groups, including age at diagnosis (38 years in each group), gender [66% female (eculizumab) versus 65% female (placebo)], and duration of gMG [9.9 (eculizumab) versus 9.2 (placebo) years]. Over 95% of patients in each group were receiving acetylcholinesterase (AchE) inhibitors, and 98% were receiving immunosuppressant therapies (ISTs). Approximately 50% of each group had been previously treated with at least 3 ISTs.</paragraph>
                        <paragraph>Eculizumab was administered according to the recommended dosage regimen [see Dosage and Administration (<linkHtml href="#s11">2.4</linkHtml>)].</paragraph>
                        <paragraph>The primary efficacy endpoint for gMG Study 1 was a comparison of the change from baseline between treatment groups in the Myasthenia Gravis-Specific Activities of Daily Living scale (MGADL) total score at Week 26. The MG-ADL is a categorical scale that assesses the impact on daily function of 8 signs or symptoms that are typically affected in gMG. Each item is assessed on a 4point scale where a score of 0 represents normal function and a score of 3 represents loss of ability to perform that function (total score 0-24). A statistically significant difference favoring eculizumab was observed in the mean change from baseline to Week 26 in MG-ADL total scores [-4.2 points in the eculizumab-treated group compared with -2.3 points in the placebo-treated group (p=0.006)].</paragraph>
                        <paragraph>A key secondary endpoint in gMG Study 1 was the change from baseline in the Quantitative Myasthenia Gravis (QMG) total score at Week 26. The QMG is a 13-item categorical scale assessing muscle weakness. Each item is assessed on a 4-point scale where a score of 0 represents no weakness and a score of 3 represents severe weakness (total score 0-39). A statistically significant difference favoring eculizumab was observed in the mean change from baseline to Week 26 in QMG total scores [-4.6 points in the eculizumab-treated group compared with -1.6 points in the placebo-treated group (p=0.001)].</paragraph>
                        <paragraph>The results of the analysis of the MG-ADL and QMG from gMG Study 1 are shown in <linkHtml href="#t20">Table 20</linkHtml>.</paragraph>
                        <table ID="t20" width="100%">
                           <caption>Table 20: Analysis of Change from Baseline to Week 26 in MG-ADL and QMG Total Scores in gMG Study 1</caption>
                           <col width="20.420%" align="left"/>
                           <col width="18.240%" align="left"/>
                           <col width="15.560%" align="left"/>
                           <col width="27.100%" align="left"/>
                           <col width="18.680%" align="left"/>
                           <tfoot>
                              <tr>
                                 <td colspan="5" align="left" valign="top">
                                    <paragraph styleCode="footnote">SEM= Standard Error of the Mean; eculizumab-LSMean = least square mean for the treatment group; Placebo-LSMean = least square mean for the placebo group; LSMean-Difference (95% CI) = Difference in least square mean with 95% confidence interval; p-values (testing the null hypothesis that there is no difference between the two treatment arms</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="5" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>a</sup>: in least square means at Week 26 using a repeated measure analysis; <sup>b</sup>: in ranks at Week 26 using a worst rank analysis).</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule">
                                    <content styleCode="bold">Efficacy Endpoints</content>
                                 </td>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">Eculizumab-LS Mean (N=62) (SEM)</content>
                                 </td>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">Placebo-LS Mean (N=63) (SEM)</content>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">Eculizumab change relative to placebo â LS Mean Difference (95% CI)</content>
                                 </td>
                                 <td align="center" valign="middle" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">p-values</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">MG-ADL</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-4.2 (0.49)</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-2.3 (0.48)</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-1.9 (-3.3, -0.6)</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">(0.006<sup>a</sup>; 0.014<sup>b</sup>)</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">QMG</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-4.6 (0.60)</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-1.6 (0.59)</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">-3.0 (-4.6, -1.3)</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">(0.001<sup>a</sup>; 0.005<sup>b</sup>)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>In gMG Study 1, a clinical response was defined in the MG-ADL total score as at least a 3-point improvement and in QMG total score as at least a 5-point improvement. The proportion of clinical responders at Week 26 with no rescue therapy was statistically significantly higher for eculizumab compared to placebo for both measures. For both endpoints, and also at higher response thresholds (â¥4-, 5-, 6-, 7-, or 8-point improvement on MG-ADL, and â¥6-, 7-, 8-, 9-, or 10-point improvement on QMG), the proportion of clinical responders was consistently greater for eculizumab compared to placebo. Available data suggest that clinical response is usually achieved by 12 weeks of eculizumab treatment.</paragraph>
                     </text>
                     <effectiveTime value="20250402"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s71">
               <id root="baaabdda-ea38-45b9-873d-b84b40cede93"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16  HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>EPYSQLI (eculizumab-aagh) injection is a sterile, preservative-free, clear to slightly opalescent and colorless solution supplied as one 300 mg/30 mL (10 mg/mL) single-dose vial per carton (NDC 51759-208-13).</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Store EPYSQLI vials in a refrigerator at 2Â°C to 8Â°C (36Â°F to 46Â°F) in the original carton to protect from light until time of use. DO NOT FREEZE. DO NOT SHAKE.</item>
                     <item>Prior to administration, if needed, unopened vials of EPYSQLI may be stored in the original carton at controlled room temperature [not more than 30Â°C (86Â°F)] for a single 1 month period and then returned to refrigeration for 3 days.</item>
                     <item>Do not use beyond the expiration date shown on the carton.</item>
                  </list>
                  <paragraph>Refer to <content styleCode="italics">Dosage and Administration (<linkHtml href="#s7">2</linkHtml>)</content> for information on the stability and storage of diluted solutions of EPYSQLI.</paragraph>
               </text>
               <effectiveTime value="20250402"/>
            </section>
         </component>
         <component>
            <section ID="s72">
               <id root="3637dfca-9c2d-4d8b-a2b3-5a9cec511185"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17  PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patients and/or caregivers to read the FDA-approved patient labeling (<linkHtml href="#s77">Medication Guide</linkHtml>).</paragraph>
               </text>
               <effectiveTime value="20250402"/>
               <component>
                  <section ID="s73">
                     <id root="21f4189f-b7f9-457f-b4a8-a4a8407eaa5d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Serious Meningococcal Infections</content>
                        </paragraph>
                        <paragraph>Advise patients of the risk of serious meningococcal infection. Inform patients of the need to complete or update their meningococcal vaccinations at least 2 weeks prior to receiving the first dose of EPYSQLI or receive antibacterial drug prophylaxis if EPYSQLI treatment must be initiated immediately and they have not been previously vaccinated. Inform patients of the requirement to be revaccinated according to current ACIP recommendations for meningococcal infection while on EPYSQLI therapy <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s18">5.1</linkHtml>)]</content>.</paragraph>
                        <paragraph>Inform patients that vaccination may not prevent serious meningococcal infection and to seek immediate medical attention if the following signs or symptoms occur <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s18">5.1</linkHtml>)]</content>:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>fever</item>
                           <item>fever and a rash</item>
                           <item>fever with high heart rate</item>
                           <item>headache with nausea or vomiting</item>
                           <item>headache and a fever</item>
                           <item>headache with a stiff neck or stiff back</item>
                           <item>confusion</item>
                           <item>muscle aches with flu-like symptoms</item>
                           <item>eyes sensitive to light</item>
                        </list>
                        <paragraph>Inform patients that they will be given a Patient Safety Card for EPYSQLI that they should carry with them at all times during and for 3 months following treatment with EPYSQLI. This card describes symptoms which, if experienced, should prompt the patient to immediately seek medical evaluation.</paragraph>
                     </text>
                     <effectiveTime value="20250402"/>
                  </section>
               </component>
               <component>
                  <section ID="s74">
                     <id root="14de435d-e781-4a52-a98d-453fe0d8bdb1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">EPYSQLI REMS</content>
                        </paragraph>
                        <paragraph>EPYSQLI is available only through a restricted program called EPYSQLI REMS <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s19">5.2</linkHtml>)]</content>.</paragraph>
                        <paragraph>Inform the patient of the following notable requirements:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Patients must receive counseling about the risk of serious meningococcal infections.</item>
                           <item>Patients must receive written educational materials about this risk.</item>
                           <item>Patients must be instructed to carry the Patient Safety Card with them at all times during and for 3 months following treatment with EPYSQLI.</item>
                           <item>Patients must be instructed to complete or update meningococcal vaccines for serogroups A, C, W, Y and B per ACIP recommendations as directed by the prescriber prior to treatment with EPYSQLI.</item>
                           <item>Patients must receive antibiotics as directed by the prescriber if they are not up to date with meningococcal vaccines and have to start EPYSQLI right away.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250402"/>
                  </section>
               </component>
               <component>
                  <section ID="s75">
                     <id root="7e4ba64e-af50-4a1c-bb0e-6fa703664865"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Other Infections</content>
                        </paragraph>
                        <paragraph>Counsel patients about gonorrhea prevention and advise regular testing for patients at-risk.</paragraph>
                        <paragraph>Inform patients that there may be an increased risk of other types of infections, particularly those due to encapsulated bacteria.</paragraph>
                        <paragraph>Aspergillus infections have occurred in immunocompromised and neutropenic patients.</paragraph>
                        <paragraph>Inform parents or caregivers of children receiving EPYSQLI for the treatment of Ahus that their child should be vaccinated against <content styleCode="italics">Streptococcus pneumoniae</content> and <content styleCode="italics">Haemophilus influenzae</content> type b (Hib) according to current medical guidelines.</paragraph>
                     </text>
                     <effectiveTime value="20250402"/>
                  </section>
               </component>
               <component>
                  <section ID="s76">
                     <id root="ca68cbfc-950c-42fd-bb5e-f3e9f936eb98"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Infusion-Related Reactions</content>
                        </paragraph>
                        <paragraph>Advise patients that administration of EPYSQLI may result in infusion-related reactions.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Discontinuation</content>
                        </paragraph>
                        <paragraph>Inform patients with PNH that they may develop serious hemolysis due to PNH when EPYSQLI is discontinued and that they will be monitored by their healthcare professional for at least 8 weeks following EPYSQLI discontinuation.</paragraph>
                        <paragraph>Inform patients with aHUS that there is a potential for TMA complications due to aHUS when EPYSQLI is discontinued and that they will be monitored by their healthcare professional for at least 12 weeks following EPYSQLI discontinuation. Inform patients who discontinue EPYSQLI to keep the  Patient Safety Card with them for three months after the last EPYSQLI dose, because the increased risk of meningococcal infection persists for several weeks following discontinuation of EPYSQLI.</paragraph>
                        <paragraph>Manufactured by:</paragraph>
                        <paragraph>Samsung Bioepis Co., Ltd.<br/>76, Songdogyoyuk-ro,<br/>Yeonsu-gu, Incheon, 21987<br/>Republic of Korea</paragraph>
                        <paragraph>US License Number 2046</paragraph>
                     </text>
                     <effectiveTime value="20250402"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="ca0dff45-bea0-40a8-9b32-a0d9fb4909d3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>Product of Australia</paragraph>
                        <paragraph>
                           <content styleCode="bold">Manufactured for:</content>
                           <br/>Teva Pharmaceuticals<br/>Parsippany, NJ 07054</paragraph>
                     </text>
                     <effectiveTime value="20250402"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s77">
               <id root="dbe06f16-e77d-4324-9fe7-4df4a6901f06"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <text>
                  <table width="100%">
                     <col width="3%" align="left"/>
                     <col width="2%" align="left"/>
                     <col width="20%" align="left"/>
                     <col width="13%" align="left"/>
                     <col width="12%" align="left"/>
                     <col width="25%" align="left"/>
                     <col width="25%" align="left"/>
                     <tfoot>
                        <tr>
                           <td colspan="6" align="left" valign="top">
                              <paragraph styleCode="footnote">This Medication Guide has been approved by the U.S. Food and Drug Administration.</paragraph>
                           </td>
                           <td align="right" valign="top">
                              <paragraph styleCode="footnote">Revised: 4/2025</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="middle"/>
                           <td align="left" valign="middle"/>
                           <td align="left" valign="middle"/>
                           <td align="left" valign="middle"/>
                           <td align="left" valign="middle"/>
                           <td align="left" valign="middle"/>
                           <td align="left" valign="middle"/>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td colspan="7" align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">MEDICATION GUIDE</content>
                              <br/>EPYSQLI<sup>Â®</sup> (eh-pis'-klee)<br/>(eculizumab-aagh)<br/>injection, for intravenous use</td>
                        </tr>
                        <tr>
                           <td colspan="7" align="left" valign="top" styleCode="Lrule Rrule">
                              <paragraph ID="p02">
                                 <content styleCode="bold">What is the most important information I should know about EPYSQLI?</content>
                                 <br/>
                                 <content styleCode="bold">EPYSQLI is a medicine that affects your immune system. EPYSQLI may lower the ability of your immune system to fight infections.</content>
                                 <br/>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">EPYSQLI increases your chance of getting serious meningococcal infections caused by</content>
                                    <content styleCode="bold italics">Neisseria meningitidis</content>
                                    <content styleCode="bold">bacteria. Meningococcal infections may quickly become life-threatening or cause death if not recognized and treated early.</content>
                                    <list listType="unordered" styleCode="Circle">
                                       <item>You must complete or update your meningococcal vaccines at least 2 weeks before your first dose of EPYSQLI.</item>
                                       <item>If you have not completed your meningococcal vaccines and EPYSQLI must be started right away, you should receive the required vaccine(s) as soon as possible.</item>
                                       <item>If you have not been vaccinated and EPYSQLI must be started right away, you should also receive antibiotics to take for as long as your healthcare provider tells you.</item>
                                       <item>If you had a meningococcal vaccine in the past, you might need additional vaccines before starting EPYSQLI. Your healthcare provider will decide if you need additional meningococcal vaccines.</item>
                                       <item>Meningococcal vaccines do not prevent all meningococcal infections. <content styleCode="bold">Call your healthcare provider or get emergency medical care right away if you get any of these signs and symptoms of a serious meningococcal infection</content>:</item>
                                    </list>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule" colspan="2"/>
                           <td align="left" valign="top" colspan="3">
                              <list listType="unordered" styleCode="Square">
                                 <item>fever</item>
                                 <item>fever with high heart rate</item>
                                 <item>headache and fever</item>
                                 <item>confusion</item>
                                 <item>muscle aches with flu-like symptoms</item>
                              </list>
                           </td>
                           <td align="left" valign="top" colspan="2" styleCode="Rrule">
                              <list listType="unordered" styleCode="Square">
                                 <item>fever and a rash</item>
                                 <item>headache with nausea or vomiting</item>
                                 <item>headache with a stiff neck or stiff back</item>
                                 <item>eyes sensitive to light</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="7" styleCode="Lrule Rrule">
                              <content styleCode="bold">Your healthcare provider will give you a Patient Safety Card about the risk of serious meningococcal infection.</content> Carry it with you at all times during treatment and for 3 months after your last dose of EPYSQLI. Your risk of meningococcal infection may continue for several weeks after your last dose of EPYSQLI. It is important to show this card to any healthcare provider who treats you. This will help them diagnose and treat you quickly.<br/>
                              <content styleCode="bold">EPYSQLI is only available through a program called the EPYSQLI Risk Evaluation and Mitigation Strategy (REMS).</content> Before you can receive EPYSQLI, your healthcare provider must:<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>enroll in the EPYSQLI REMS program</item>
                                 <item>counsel you about the risk of serious meningococcal infections</item>
                                 <item>give you information about the signs and symptoms of serious meningococcal infection</item>
                                 <item>make sure that you are vaccinated against serious infections caused by meningococcal bacteria and that you receive antibiotics if you need to start EPYSQLI right away and you are not up to date on your vaccines</item>
                                 <item>give you a <content styleCode="bold">Patient Safety Card</content> about your risk of meningococcal infection, as discussed above<br/>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="7" align="left" valign="top" styleCode="Lrule Rrule">
                              <content styleCode="bold">EPYSQLI may also increase the risk of other types of serious infections</content> caused by encapsulated bacteria, including <content styleCode="italics">Streptococcus pneumoniae</content>, <content styleCode="italics">Haemophilus influenzae</content>, and <content styleCode="italics">Neisseria gonorrhoeae</content>.<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>If your child is treated with EPYSQLI, your child should receive vaccines against <content styleCode="italics">Streptococcus pneumoniae</content> and <content styleCode="italics">Haemophilus influenzae type b</content> (Hib).</item>
                                 <item>Certain people may be at risk of serious infections with gonorrhea. Talk to your healthcare provider about whether you are at risk for gonorrhea infection, about gonorrhea prevention, and regular testing.</item>
                                 <item>Certain fungal infections (aspergillus) may also happen if you take EPYSQLI and have a weak immune system or a low white blood cell count.<br/>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="7" align="left" valign="top" styleCode="Botrule Lrule Rrule">For more information about side effects, see â<content styleCode="bold">
                                 <linkHtml href="#p01">What are the possible side effects of EPYSQLI?</linkHtml>
                              </content>â</td>
                        </tr>
                        <tr>
                           <td colspan="7" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">What is EPYSQLI?</content>
                              <br/>EPYSQLI is a prescription medicine used to treat:<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>people with paroxysmal nocturnal hemoglobinuria (PNH).</item>
                                 <item>people with atypical hemolytic uremic syndrome (aHUS).<br/>EPYSQLI is not for use in treating people with Shiga toxin E. coli related hemolytic uremic syndrome (STEC- HUS).</item>
                                 <item>adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody positive.It is not known if EPYSQLI is safe and effective in children with PNH or gMG.<br/>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="7" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Who should not receive EPYSQLI?</content>
                              <br/>
                              <content styleCode="bold">Do not receive EPYSQLI if you</content> have a serious meningococcal infection when you are starting EPYSQLI treatment.</td>
                        </tr>
                        <tr>
                           <td colspan="7" align="left" valign="top" styleCode="Lrule Rrule">
                              <content styleCode="bold">Before you receive EPYSQLI, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>have an infection or fever.</item>
                                 <item>are pregnant or plan to become pregnant. It is not known if EPYSQLI will harm your unborn baby.</item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known if EPYSQLI passes into your breast milk.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="7" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Tell your healthcare provider about all the medicines you take</content>, including prescription and over-the-counter medicines, vitamins, and herbal supplements. EPYSQLI and other medicines can affect each other causing side effects.<br/>Know the medications you take and the vaccines you receive. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.</td>
                        </tr>
                        <tr>
                           <td colspan="7" align="left" valign="top" styleCode="Lrule Rrule">
                              <paragraph ID="p03">
                                 <content styleCode="bold">How should I receive EPYSQLI?</content>
                                 <br/>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Your healthcare provider will give you EPYSQLI into your vein through an intravenous (IV) line usually over 35 minutes in adults and 1 to 4 hours in children.</item>
                                 <item>Adults will usually receive an EPYSQLI infusion:<list listType="unordered" styleCode="Circle">
                                       <item>weekly for 5 weeks, then</item>
                                       <item>every 2 weeks.</item>
                                    </list>
                                 </item>
                                 <item>Children less than 18 years of age, your healthcare provider will decide how often you will receive EPYSQLI depending on your age and body weight.</item>
                                 <item>After each infusion, you should be monitored for at least 1 hour for infusion-related reactions. See â<content styleCode="bold">
                                       <linkHtml href="#p01">What are the possible side effects of EPYSQLI?</linkHtml>
                                    </content>â If you have an infusion-related reaction during your EPYSQLI infusion, your healthcare provider may decide to give EPYSQLI more slowly or stop your infusion.</item>
                                 <item>If you miss an EPYSQLI infusion, call your healthcare provider right away.</item>
                                 <item>
                                    <content styleCode="bold">If you have PNH, your healthcare provider will need to monitor you closely for at least 8 weeks after stopping EPYSQLI. Stopping treatment with EPYSQLI may cause breakdown of your red blood cells due to PNH.<br/>Symptoms or problems that can happen due to red blood cell breakdown include</content>:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td align="left" valign="top" colspan="3">
                              <list listType="unordered" styleCode="Circle">
                                 <item>drop in the number of your red blood cell count</item>
                                 <item>kidney problems</item>
                              </list>
                           </td>
                           <td align="left" valign="top" colspan="2">
                              <list listType="unordered" styleCode="Circle">
                                 <item>drop in your platelet</item>
                                 <item>counts</item>
                                 <item>blood clots</item>
                              </list>
                           </td>
                           <td align="left" valign="top" styleCode="Rrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>confusion</item>
                                 <item>difficulty breathing</item>
                                 <item>chest pain</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="7" styleCode="Lrule Rrule">
                              <list listType="unordered">
                                 <item>
                                    <content styleCode="bold">If you have aHUS, your healthcare provider will need to monitor you closely for at least 12 weeks after stopping EPYSQLI for signs of worsening aHUS symptoms or problems related to abnormal clotting (thrombotic microangiopathy).<br/>Symptoms or problems that can happen with abnormal clotting may include</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule"/>
                           <td align="left" valign="top" colspan="2">
                              <list listType="unordered" styleCode="Circle">
                                 <item>stroke</item>
                                 <item>difficulty breathing</item>
                              </list>
                           </td>
                           <td align="left" valign="top" colspan="2">
                              <list listType="unordered" styleCode="Circle">
                                 <item>confusion</item>
                                 <item>kidney problems</item>
                              </list>
                           </td>
                           <td align="left" valign="top">
                              <list listType="unordered" styleCode="Circle">
                                 <item>seizure</item>
                                 <item>swelling in arms or legs</item>
                              </list>
                           </td>
                           <td align="left" valign="top" styleCode="Rrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>chest pain (angina)</item>
                                 <item>a drop in your platelet count</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="7" align="left" valign="top" styleCode="Lrule Rrule">
                              <paragraph ID="p01">
                                 <content styleCode="bold">What are the possible side effects of EPYSQLI?</content>
                                 <br/>
                                 <content styleCode="bold">EPYSQLI can cause serious side effects including:</content>
                                 <br/>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>See <content styleCode="bold">â<linkHtml href="#p02">What is the most important information I should know about EPYSQLI?</linkHtml>â</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Serious infusion-related reactions</content>. Serious infusion-related reactions can happen during your EPYSQLI infusion. Tell your healthcare provider or nurse right away if you get any of these symptoms during your EPYSQLI infusion:<list listType="unordered" styleCode="Circle">
                                       <item>chest pain</item>
                                       <item>trouble breathing or shortness of breath</item>
                                       <item>swelling of your face, tongue, or throat</item>
                                       <item>feel faint or pass out</item>
                                    </list>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="7" align="left" valign="top" styleCode="Lrule Rrule">If you have an infusion-related reaction to EPYSQLI, your healthcare provider may need to infuse EPYSQLI more slowly, or stop EPYSQLI. See â<content styleCode="bold">
                                 <linkHtml href="#p03">How will I receive EPYSQLI?</linkHtml>
                              </content>â<br/>
                              <content styleCode="bold">The most common side effects in people with PNH treated with EPYSQLI include:</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" align="left" valign="top" styleCode="Lrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>headache</item>
                                 <item>pain or swelling of your nose or throat (nasopharyngitis)</item>
                              </list>
                           </td>
                           <td colspan="2" align="left" valign="top" styleCode="Rrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>back pain</item>
                                 <item>nausea</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="7" align="left" valign="top" styleCode="Lrule Rrule">
                              <content styleCode="bold">The most common side effects in people with aHUS treated with EPYSQLI include:</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule" colspan="3" align="left" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>headache</item>
                                 <item>diarrhea</item>
                                 <item>high blood pressure (hypertension)</item>
                                 <item>common cold (upper respiratory infection)</item>
                              </list>
                           </td>
                           <td align="left" valign="top" colspan="2">
                              <list listType="unordered" styleCode="Disc">
                                 <item>stomach-area( abdominal) pain</item>
                                 <item>vomiting</item>
                                 <item>pain or swelling of</item>
                                 <item>your nose or throat     (nasopharyngitis)</item>
                              </list>
                           </td>
                           <td align="left" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>low red blood cell count (anemia)</item>
                                 <item>cough</item>
                                 <item>swelling of legs or</item>
                                 <item>feet (peripheral  edema)</item>
                              </list>
                           </td>
                           <td align="left" valign="top" styleCode="Rrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>nausea</item>
                                 <item>urinary tract infections</item>
                                 <item>fever</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="7" align="left" valign="top" styleCode="Lrule Rrule">
                              <content styleCode="bold">The most common side effects in people with gMG treated with EPYSQLI include:</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>muscle and joint (musculoskeletal) pain</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="7" align="left" valign="top" styleCode="Botrule Lrule Rrule">Tell your healthcare provider about any side effect that bothers you or that does not go away. These are not all the possible side effects of EPYSQLI.<br/>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</td>
                        </tr>
                        <tr>
                           <td colspan="7" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">General information about the safe and effective use of EPYSQLI.</content>
                              <br/>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your pharmacist or healthcare provider for information about EPYSQLI that is written for health professionals.</td>
                        </tr>
                        <tr>
                           <td colspan="7" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">What are the ingredients in EPYSQLI?</content>
                              <br/>Active ingredient: eculizumab-aagh<br/>Inactive ingredients: dibasic sodium phosphate, monobasic sodium phosphate, polysorbate 80 (vegetable origin), trehalose, and Water for Injection.<br/>Manufactured by Samsung Bioepis Co., Ltd.,<br/> 76, Songdogyoyuk-ro, Yeonsu-gu, Incheon 21987 Republic of Korea.<br/> US License Number 2046<br/>Manufactured for Teva Pharmaceuticals<br/>Parsippany, NJ 07054</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250402"/>
            </section>
         </component>
         <component>
            <section>
               <id root="f66b9bc6-845f-449e-a99e-35e2cba7a3c1"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 30 mL Vial Label</title>
               <text>
                  <paragraph>NDC 51759-208-13</paragraph>
                  <paragraph>Epysqli<sup>Â®</sup>
                     <br/>(eculizumab-aagh)<br/>Injection<br/>300 mg/30 mL<br/>(10 mg/mL)</paragraph>
                  <paragraph>For Intravenous Infusion<br/>Must dilute before use.<br/>30 mL Single-Dose Vial<br/>Discard Unused Portion</paragraph>
                  <paragraph>000303748-01</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
               </text>
               <effectiveTime value="20250402"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>PRINCIPAL DISPLAY PANEL - 30 mL Vial Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="epysql-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="6c333fc5-41bd-400d-a86f-49b526c0c1b2"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 30 mL Vial Carton</title>
               <text>
                  <paragraph>NDC 51759-208-13</paragraph>
                  <paragraph>Epysqli<sup>Â®</sup>
                     <br/>(eculizumab-aagh)<br/>Injection<br/>300 mg/30 mL<br/>(10 mg/mL)</paragraph>
                  <paragraph>For Intravenous Infusion</paragraph>
                  <paragraph>Must dilute before use.</paragraph>
                  <paragraph>ATTENTION PHARMACIST:<br/>Each patient is required to<br/>receive the enclosed<br/>Medication Guide.</paragraph>
                  <paragraph>One 30 mL Single-Dose Vial.</paragraph>
                  <paragraph>Discard Unused Portion.</paragraph>
                  <paragraph>SAMSUNG<br/> BIOEPIS | teva</paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
               </text>
               <effectiveTime value="20250402"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>PRINCIPAL DISPLAY PANEL - 30 mL Vial Carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="epysql-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>